Response Biomedical (RPBIF) 10-K 19 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 28, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	RESPONSE BIOMEDICAL CORP
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		9,759,560
Entity Public Float			$4,350,782
Amendment Flag	FALSE
Entity Central Index Key	806888
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (CAD)	Dec. 31, 2014		Dec. 31, 2013
Current
Cash and cash equivalents	3,221,000		2,958,000
Trade receivables, net [note 6]	702,000		875,000
Other receivables	89,000		112,000
Inventories [note 7]	2,056,000		2,250,000
Prepaid expenses and other	183,000		123,000
Deferred financing costs - current portion [note 11]	88,000		73,000
Total current assets	6,339,000		6,391,000
Deferred financing costs [note 11]	45,000
Long-term prepaid expenses	93,000		93,000
Restricted deposits [note 10]	901,000		901,000
Property, plant and equipment [note 8]	6,250,000		6,819,000
Total assets	13,628,000		14,204,000
Current
Accounts payable and accrued liabilities [notes 6 and 9]	3,867,000		2,727,000
Term loan - current portion [note 11]	494,000
Lease inducements - current portion [note 10]	169,000		170,000
Repayable leasehold improvement allowance - current portion [notes 6 and 10]	461,000	[1]	413,000	[1]
Deferred revenue - current portion	871,000		62,000
Warrant liability [notes 5 and 12]	1,249,000		5,251,000
Total current liabilities	7,111,000		8,623,000
Lease inducements [note 10]	1,197,000		1,366,000
Term loan [note 11]	1,004,000
Repayable leasehold improvement allowance [note 10]	5,208,000		5,669,000
Deferred revenue	2,000		28,000
	14,522,000		15,686,000
Commitments [note 15]	0		0
Shareholders' deficit
Common shares [note 12]	104,124,000		101,945,000
Additional paid-in capital [note 12]	15,241,000		14,742,000
Deficit	-120,259,000		-118,169,000
Total shareholders' deficit	-894,000		-1,482,000
	13,628,000		14,204,000
[1]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the year ended December 31, 2014 amounted to $413,000 [2013 - $370,000; 2012 - $332,000], respectively. Interest payments for the year ended December 31, 2014 amounted to $649,000 [2013 - $691,000; 2012 - $730,000].

Consolidated_Statements_of_Los

Consolidated Statements of Loss and Comprehensive Loss (CAD)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
REVENUE
Product sales [note 16]	10,828	11,531	11,750
Collaborative revenue [notes 2 and 13]	186
Total revenue	11,014	11,531	11,750
Cost of sales [notes 7, 8, 12, and 15]	6,647	6,588	7,504
Gross profit	4,367	4,943	4,246
EXPENSES [notes 8, 10, 12, 13 and 15]
Research and development	3,525	2,402	2,953
General and administrative	3,297	3,574	4,101
Sales and marketing	2,578	2,171	1,395
Total operating expenses	9,400	8,147	8,449
OTHER EXPENSES (INCOME)
Interest expense and amortization of deferred financing costs and debt discount [note 11]	874	696	734
Interest income	-15	-15	-22
Other income		-58
Income tax expense	68	41
Foreign exchange loss	132	16	2
Unrealized loss (gain) on revaluation of warrant liability [note 5]	-4,002	2,114	364
Total other expenses (income)	-2,943	2,794	1,078
Net loss and comprehensive loss for the period	-2,090	-5,998	-5,281
Loss per common share - basic and diluted[note 12] (in Dollars per share)	-0.26	-0.89	-0.82
Weighted average number of common shares outstanding– basic and diluted [note 12] (in Shares)	8,025,143	6,747,369	6,437,158

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity/(Deficit) (CAD)	Private Placement [Member]	Private Placement [Member]	Private Placement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
	Common Stock [Member]	Additional Paid-in Capital [Member]
Balance at Dec. 31, 2012				99,289,000	13,203,000	-112,171,000	321,000
Balance (in Shares) at Dec. 31, 2012				6,455,206
Net loss						-5,998,000	-5,998,000
Private placement, net of issue costs	2,055,000	695,000	2,750,000	562,000			562,000
Private placement, net of issue costs (in Shares)	1,273,117			122,458
Net shares issued upon exercise of warrants	2,055,000	695,000	2,750,000	562,000			562,000
Net shares issued upon exercise of warrants (in Shares)	1,273,117			122,458
Net shares issued upon conversion of restricted share units				39,000	-39,000
Net shares issued upon conversion of restricted share units (in Shares)				20,144
Stock-based compensation expense					660,000		660,000
Restricted share units					223,000		223,000
Balance at Dec. 31, 2013				101,945,000	14,742,000	-118,169,000	-1,482,000
Balance (in Shares) at Dec. 31, 2013				7,870,925
Net loss						-2,090,000	-2,090,000
Private placement, net of issue costs	2,024,000		2,024,000
Private placement, net of issue costs (in Shares)	1,800,000
Net shares issued upon exercise of warrants	2,024,000		2,024,000
Net shares issued upon exercise of warrants (in Shares)	1,800,000
Net shares issued upon conversion of restricted share units				155,000	-155,000
Net shares issued upon conversion of restricted share units (in Shares)				88,635
Net warrants issued per terms of loan					113,000		113,000
Stock-based compensation expense					381,000		381,000
Restricted share units					160,000		160,000
Balance at Dec. 31, 2014				104,124,000	15,241,000	-120,259,000	-894,000
Balance (in Shares) at Dec. 31, 2014				9,759,560

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (CAD)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net loss for the year	-2,090	-5,998	-5,281
Add (deduct) items not involving cash:
Depreciation of property, plant and equipment	994	992	1,143
Amortization of deferred lease inducements	-170	-171	-165
Amortization of deferred financing costs	99
Amortization of discount on debt	34
Stock-based compensation	381	660	614
Unrealized loss (gain) on revaluation of warrant liability	-4,002	2,114	364
Other non-cash items	75
Changes in non-cash working capital:
Trade receivables	173	658	79
Other receivables	23	25	-93
Inventories	194	-459	414
Prepaid expenses and other	-60	88	38
Accounts payable and accrued liabilities	1,285	998	-1,630
Deferred revenue	783	-181	-115
Cash used in operating activities	-2,281	-1,274	-4,632
INVESTING ACTIVITIES
Purchase of property, plant and equipment	-410	-196	-311
Cash used in investing activities	-410	-196	-311
FINANCING ACTIVITIES
Repayment of repayable leasehold improvement allowance	-413	-371	-332
Proceeds from issuance of common shares, net of share issue costs	2,024	2,055	0
Proceeds from issuance of warrants, net of warrant issue costs	0	695	0
Proceeds from debt	1,661	0	0
Repayment of long term debt	-159	0	0
Debt financing cost	-159	-31	0
Cash provided by (used in) financing activities	2,954	2,348	-332
Increase /(Decrease) in cash during the year	263	878	-5,275
Cash and cash equivalents, beginning of year	2,958	2,080	7,355
Cash and cash equivalents, end of year	3,221	2,958	2,080
Supplemental Disclosure:
Interest Paid in cash	731	696	755
Taxes Paid in cash	50	27

Note_1_Description_of_Business

Note 1 - Description of Business	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	1. DESCRIPTION OF BUSINESS
	Response Biomedical Corp. (“Response” or the “Company”) was incorporated on August 20, 1980 under the predecessor to the Business Corporations Act (British Columbia). The Company’s wholly owned US subsidiary, Response Point of Care Inc., was incorporated on November 9, 2012 in the State of Delaware. The Company is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical point of care (POC), laboratory and on-site environmental testing markets. POC and on-site diagnostic tests (or assays) are simple, non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. Since 1996, the Company has developed and commercialized a proprietary diagnostic system called RAMP®.
	The RAMP® System is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test, establishing a new paradigm in diagnostic testing. Immunoassays are extremely sensitive and specific tests used to identify and measure small quantities of materials, such as proteins. A large variety of biological molecules and inorganic materials can be targeted. Accordingly, the RAMP® technology is applicable to multiple distinct market segments and many products within those segments. RAMP® tests are now commercially available for use in the early detection of heart attack, congestive heart failure, influenza A+B, the respiratory syncytial virus, environmental detection of West Nile Virus, and biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Note_2_Basis_of_Presentation_a

Note 2 - Basis of Presentation and Going Concern Uncertainty	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2. BASIS OF PRESENTATION AND GOING CONCERN UNCERTAINTY
	These consolidated financial statements have been prepared by management in Canadian dollars in accordance with United States generally accepted accounting principles (“U.S. GAAP”).
	Going Concern Uncertainty
	The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.
	During the year ended December 31, 2014, the Company has incurred a net loss of $2.1 million and negative cash flows from operations of $2.3 million. As of December 31, 2014, the Company had a cash balance of $3.2 million, an accumulated deficit of $120.3 million, a shareholders’ deficit of $894,000, and a negative working capital balance of $772,000. In addition, the Company has various operating leases and purchase commitments for inventory (refer to note 15). Included in current liabilities is a warrant liability in the amount of $1.2 million that is required to be measured at fair value and is presented as a current liability in accordance with Accounting Standards Codification Topic 815 – Derivatives and Hedging (“ASC 815”). Each warrant may only be exercised on a net cashless exercise basis and no warrant may be exercised at a time when the exercise price equals or exceeds the current market price meaning the potential settlement of any warrant does not require any cash disbursement. Without taking into account the warrant liability mentioned above, current assets exceed current liabilities by $477,000.
	The ability of the Company to continue as a going concern is uncertain and dependent on the Company’s ability to obtain additional financing and/or achieve cash flow positive operations. Management has, thus far, financed the operations through a series of equity financings, debt financing, and collaborative arrangements. On October 15, 2014, the Company announced that it had entered into a funded Technology Development Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. (“Joinstar”) to support the co-development by Response and Joinstar of components and multiple assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. Joinstar related entities purchased 1,800,000 common shares of Response at a price of $1.21 per share for net proceeds of $2.0 million on December 12, 2014. Under the terms of the Technology Development Agreement, Joinstar paid US$560,000 upon the signing of the Technology Development Agreement on October 15, 2014 and US$720,000 upon the signing of the Collaborative Agreement, which was signed on February 16, 2015. Response is eligible to receive a further US$2.52 million in development milestones over the planned fifteen month project period. In conjunction with the signing of the Collaborative Agreement, Response and Joinstar entered into a definitive Supply Agreement whereby Response will provide certain materials required for Joinstar to manufacture and sell the developed assays specifically to run on their analyzer. Under the terms of the Supply Agreement, Response is eligible to receive a guaranteed US$2.13 million in revenue based payments over the first five years of commercialization of the co-developed assays. In addition to the Joinstar agreements, on February 11, 2014, the Company secured a US$2.5 million term loan from Silicon Valley Bank (“SVB”) of which only US$1.5 million was drawn down. Refer to note 11 for the significant terms of the loan. On October 1, 2014 and November 3, 2014, the Company announced that it had breached certain financial covenants of the original term loan agreement. The Company subsequently entered into forbearance agreements with SVB in which SVB agreed not to exercise its rights in respect of the breach or anticipated breach until December 15, 2014. The Company then renegotiated the terms of the term loan and, on December 15, 2014, announced that it had entered into an amendment to the original term loan agreement with SVB. Under the amendment, SVB agreed to continue to advance the remaining outstanding principal of US$1.4 million for the same term and interest rate, waive its rights in respect of the previously announced breaches of certain financial covenants and to remove any future minimum revenue and liquidity ratio financial covenants. In addition, SVB received additional warrants and will receive a final payment of up to 4% of the principal advanced. Refer to note 11 for the significant terms to the loan.
	Management believes that, with the signing and targeted execution under the new Joinstar Agreements and the renegotiation of the term loan with SVB, based on the current level of operations and excluding out of the ordinary cash management measures, the Company’s cash and cash equivalent balances, including cash generated from operations, will be sufficient to meet the anticipated cash requirements through the next twelve months. However, due to the Company’s history of losses, there is substantial doubt over the Company’s ability to continue as a going concern as it is dependent on meeting the development milestones required to earn the additional US$2.52 million in development fees under the Collaboration Agreement with Joinstar or achieving profitable operations, the outcomes of which cannot be predicted at this time. The consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Note_3_Significant_Accounting_

Note 3 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies is as follows:
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation.
	Use of estimates
	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Areas of significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, recoverability of long-lived assets and provisions for doubtful accounts, inventory obsolescence, inventory valuation, warranty accruals, and going concern assessments. Actual results could differ from those estimates.
	Certain Significant Risks and Uncertainties
	The Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material adverse effect on its future financial position or results of operations: continued regulatory compliance or regulatory changes; the ability to develop new products and services that are accepted in the marketplace; competition, including, but not limited to, pricing and products or product features and services; litigation or other claims; the adequate and timely sourcing and manufacturing of inventories; and the hiring, training and retention of key employees.
	Cash equivalents
	The Company considers all highly liquid investments with an original maturity of 90 days or less, when acquired, to be cash equivalents.
	Inventories
	Raw material, finished goods and work in progress inventories are carried at the lower of actual cost, determined on a first-in first-out basis, and market value. The cost of finished goods and work in progress inventories includes direct materials, direct labour and applicable overhead. The Company writes down its inventory balances for estimates of excess and obsolete amounts. These write-downs are recorded as a component of cost of sales. At the point of the write-down, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
	Property, plant and equipment
	Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives using the straight-line method as follows:
	Office and laboratory furniture and equipment (years)	5
	Office and laboratory computer equipment (years)	3
	Computer software (years)	2
	Manufacturing equipment (years)	5 – 7
	Manufacturing molds (years)	2
	Leasehold improvements	Initial term of lease
	Long Lived Asset Impairment
	Long-lived assets to be held and used by the Company are periodically reviewed to determine whether any events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. For long-lived assets to be held and used, the Company bases its evaluation on impairment indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements, as well as other external market conditions or factors that may be present. In the event that facts and circumstances indicate that the carrying amount of an asset may not be recoverable and an estimate of future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss will be recognized for the difference between the carrying value and the fair value.
	Leases
	Leases are classified as either capital or operating leases. Leases that transfer substantially all the benefits and risks of ownership of the property to the Company are accounted for as capital leases. All other leases are accounted for as operating leases wherein rental payments are expensed in a manner that results in the total rent payments being recognized on a straight-line basis over the term of the lease.
	Deferred lease inducements
	Lease inducements arising from rent-free inducements and non-repayable leasehold improvement allowances received from the landlord are being amortized over the term of the lease on a straight-line basis.
	Revenue recognition
	Product sales are recognized when legal title passes to distributors or customers, the sales price is fixed and determinable, collection of the resulting receivables is reasonably assured and no uncertainties with regard to customer acceptance exist. Sales are recorded net of discounts and sales returns.
	When arrangements include multiple elements, we use objective evidence of fair value to allocate revenue to the elements, and recognize revenue when the criteria for revenue recognition have been met for each element, in accordance with authoritative guidance on multiple-element arrangements.
	Upfront fees from collaborative research arrangements that are non-refundable, require the ongoing involvement of the Company and are directly linked to specific milestones are deferred and amortized into income as services are rendered. Upfront fees from collaborative research arrangements that are non-refundable, require the ongoing involvement of the Company and are not directly linked to specific milestones are deferred and amortized into income on a straight-line basis over the term of ongoing development. Upfront fees from collaborative research arrangements that are refundable are deferred and recognized once the refundable period has lapsed.
	Accounts Receivable
	For product sales, the Company typically invoices its customers at shipment for the sales order value of products shipped. For contract revenue, invoicing occurs based upon the terms of the specific research contract, typically one month in arrears for services rendered and any other allowable direct costs. Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company does not have any off-balance sheet credit exposure related to any of its customers.
	Allowance for Doubtful Accounts
	The Company evaluates the collectability of accounts receivable based on a combination of factors. In cases where the Company becomes aware of circumstances that may impair a specific customer’s ability to meet its financial obligations subsequent to the original sale, the Company will record an allowance against amounts due, and thereby reduce the net recognized receivable to the amount the Company reasonably believes will be collected. For all other customers, the Company recognizes an allowance for doubtful accounts based on the length of time the receivables are past due and consideration of other factors such as industry conditions, the current business environment and its historical experience.
	Deferred Financing Costs
	The Company capitalizes incremental costs directly attributable to obtaining debt. The deferred financing costs are subsequently amortized using the effective interest rate method to interest expense over the contractual life of the debt. Under a modification to a debt arrangement, only the incremental costs directly paid to the lender are capitalized and amortized over the contractual life of the debt. All incremental costs paid to third parties are expensed when incurred and are included in general and administrative expenses on the consolidated statements of loss and comprehensive loss.
	Warranty accrual
	The Company offers a standard limited warranty on its products. The Company estimates costs that may be incurred under its warranty program as liabilities at the time the products are sold. Factors that affect the Company’s warranty liability include the number of units sold, anticipated rate of warranty claims, and costs per claim, which require management to make estimates about future costs. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. The initial recognition of and subsequent adjustments to the warranty accrual are recorded to cost of sales.
	Research and development costs
	Research and development costs are expensed as incurred and include expenses associated with new product research and regulatory activities.
	Shipping and Handling Costs
	Shipping and handling costs are included in cost of revenues and are recognized as a period expense during the period in which they are incurred.
	Stock-based compensation
	The Company uses the fair value method of accounting for all stock-based awards for non-employees and for all stock-based awards to employees that were granted, modified or settled since January 1, 2003. The fair value of stock options is determined using the Black-Scholes option-pricing model, which requires certain assumptions, including future stock price volatility, estimated forfeiture rates and expected time to exercise. Stock-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those stock-based awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Changes to any of these assumptions could produce different fair values for stock-based compensation. The expense is amortized on a straight-line basis over the graded vesting period.
	Restricted deposits
	Restricted deposits consist of long-term deposits pledged as security as part of certain contractual obligations. The interest earned on these deposits is recorded in interest income on the consolidated statements of loss and comprehensive loss.
	Financial Instruments
	Financial instruments include cash, cash equivalents, receivables, restricted deposits, accounts payable, accrued and other liabilities, term loan, warrant liability, and the repayable leasehold improvement allowance. The Company has classified restricted deposits as held-to-maturity. Trade receivables and other receivables are classified as loans and receivables. Accounts payable, accrued and other liabilities, term loan, warrant liability and the repayable leasehold improvement allowance are classified as other financial liabilities.
	Held-for-trading financial instruments are initially measured at fair value with subsequent changes in fair value recorded to net income. Held-to-maturity investments are measured at amortized cost using the effective interest method with changes in amortized cost recorded to net income. Loans and receivables and other financial liabilities are initially measured at amortized cost with subsequent changes in amortized cost recorded to net income. Transaction costs (except for transaction costs related to held-for-trading financial instruments, which are expensed as, incurred) are included in the carrying amounts of financial instruments as they are carried on the consolidated balance sheet.
	Warrants
	The Company accounts for warrants, issued in the 2011 rights offering, pursuant to the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock. The Company classifies warrants on the consolidated balance sheet as a liability that is revalued at each balance sheet date subsequent to the initial issuance. Determining the appropriate fair-value model, and calculating the fair value of warrants requires considerable judgment, including estimating stock price volatility and expected warrant life. The computation of expected volatility was based on the historical volatility of shares of the Company’s common stock for a period that coincides with the expected life of the warrants. A small change in the estimates used may have a relatively large change in the estimated valuation. The Company uses the Black-Scholes pricing model to value the warrants. Changes in the fair market value of the warrants are reflected in the consolidated statement of loss as Unrealized (gain)/loss on revaluation of warrant liability
	Foreign currency translation
	Monetary items denominated in foreign currencies are translated into Canadian dollars using exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expense items are translated at the average exchange rate for the period. Foreign exchange gains and losses are included in the determination of loss for the year.
	Income taxes
	The Company accounts for income taxes using the liability method of tax allocation. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases. Deferred income tax assets and liabilities are measured using substantively enacted income tax rates expected to apply to taxable income in the years in which temporary differences are expected to reverse. The effect on deferred income tax assets and liabilities of a change in substantively enacted rates is included in earnings in the period that includes the substantive enactment date. Deferred income tax assets, net of a valuation allowance, are recorded in the consolidated financial statements if realization is considered more likely than not.
	The Company accounts for uncertain tax positions using a “more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company includes interest and penalties related to gross unrecognized tax benefits in the provision for income taxes.
	Scientific Research and Development Tax Credits
	The benefits of tax credits for scientific research and development expenditures are recognized in the year the qualifying expenditure is made provided there is reasonable assurance of recoverability. The tax credits recorded are based on the Company’s estimates of amounts expected to be recovered and are subject to audit by taxation authorities. All qualifying expenditures are eligible for non-refundable tax credits only.
	Loss per common share
	Basic loss per common share is calculated using the weighted average number of common shares outstanding during the year, excluding contingently issuable shares. Diluted loss per common share is computed in accordance with the treasury stock method that uses the weighted average number of common shares outstanding during the period. The effect of potentially issuable common shares from outstanding stock options and outstanding warrants is anti-dilutive for all periods presented.
	Segment Information
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its senior management team. The Company has one operating segment that is dedicated to the manufacture and sale of RAMP® tests. In note 16, the Company discloses information about Products and Services, Geographic Areas, and Major Customers.

Note_4_Recent_Accounting_Prono

Note 4 - Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	4. RECENT ACCOUNTING PRONOUNCEMENTS
	Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This pronouncement is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures.
	In August 2014, the FASB issued Accounting Standards Updated, or ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 2015-40) (“ASU 2014-15”). ASU 2014-15 provides guidance to U.S. GAAP about management’s responsibility to evaluate whether there is a substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. This new rule requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles currently in the U.S. auditing standards. Specifically, ASU 2014-15 (1) defines the term substantial doubt, (2) requires an evaluation of every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires an express statement and other disclosures when substantial doubt is not alleviated, and (5) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This guidance is effective for annual periods ending after December 15, 2016. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures

Note_5_Fair_Value_Measurements

Note 5 - Fair Value Measurements

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

5. FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (“exit price”) in an orderly transaction between market participants at the measurement date. Fair value measurements of financial instruments are determined by using a fair value hierarchy that prioritizes the inputs to valuation techniques into three levels according to the relative reliability of the inputs used to estimate the fair values.

The three levels of inputs used to measure fair value are as follows:

Level 1 – Unadjusted quoted prices in active markets for identical financial instruments;

Level 2 – Inputs other than quoted prices that are observable for the financial instrument either directly or indirectly; and

Level 3 – Inputs that are not based on observable market data.

In determining fair value measurements, the Company uses the most observable inputs when available.

For certain of the Company’s financial instruments, including cash and cash equivalents, trade receivables, other receivables, and accounts payable and accrued liabilities the carrying amounts approximate fair values due to their short-term nature. The carrying value of the restricted deposits approximates its fair value due to the nature of the cash deposit. The fair value of the term loan approximates its carrying value as the term loan with SVB was secured during the first quarter of 2014 and renegotiated in the fourth quarter of 2014 and therefore approximates the current market rate for the term loan. The fair value of the repayable leasehold improvement allowance approximates its carrying value as the fixed interest rate of 11% is considered to approximate the current market rate.

The fair value hierarchy level at which a financial instrument is categorized is determined on the basis of the lowest level input that is significant to the fair value measurement (in thousands):

Financial Instrument carried at fair value as of December 31, 2014 (in thousands)

Level 1

Level 2

Level 3

Total

Liabilities

$

$

$

$

Warrant Liability

-

-

1,249

1,249

Financial Instrument carried at fair value as of December 31, 2013 (in thousands)

Level 1

Level 2

Level 3

Total

Liabilities

$

$

$

$

Warrant Liability

-

-

5,251

5,251

As of December 31, 2014, the warrant liability is recorded at its fair value of $1.2 million. The Company reassesses the fair value of the common stock warrants at each reporting date utilizing a Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price volatility, contractual term of the warrant, and risk-free interest rate (refer to note 12[g]). The computation of expected volatility was based on the historical volatility of the Company’s stock. A small change in the estimates used in the Black-Scholes pricing model may have a relatively large change in the estimated valuation of the common stock warrants.

The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the year ended December 31, 2014 (in thousands):

Balance at

Balance at

31-Dec-13

Unrealized loss

Exercise of Warrants

31-Dec-14

Warrant Liability

5,251

(4,002

)

-

1,249

Quantitative information about unobservable inputs used in Level 3 fair value measurements is presented below:

Valuation Technique

Unobservable Input

As at December 31, 2014

As at December 31, 2013

Warrant Liability

Option Model

Stock Price Volatility

106%

140%

A 5% increase or decrease in stock price volatility would cause an approximate corresponding $82,000 increase or decrease to the Warrant Liability ($100,000 – December 31, 2013).

Note_6_Financial_Instruments

Note 6 - Financial Instruments	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Financial Instruments Disclosure [Text Block]	6. FINANCIAL INSTRUMENTS
	Credit Risk
	Credit risk is the risk of a financial loss if a customer or counterparty to a financial instrument fails to meet its obligations under a contract. The risk arises primarily from the Company’s cash, cash equivalents, restricted deposits and receivables from customers.
	Cash, cash equivalents and restricted deposits are placed with high quality financial institutions and are regularly monitored by management. These deposits are in excess of the amount of the insurance provided by governmental agencies on such deposits. To date, the Company has not experienced any losses on such deposits.
	The Company’s exposure to credit risk related to its receivables is dependent upon the characteristics of each customer. The Company continually monitors the credit of its customers and requires orders to be prepaid by certain customers.
	The Company is subject to concentration risk related to its accounts receivable. The Company defines concentration risk as customers whose outstanding receivable is 10% or greater than the total receivable balance or who represent 10% or greater of total revenue. At December 31, 2014, four customers represent 87% [2013 - three customers represent 74%] of the trade receivables balance. Refer to note 16 for a discussion of concentration risk on the Company’s revenues.
	The Company reviews the collectability of its accounts receivable on a regular basis and establishes an allowance for doubtful accounts based on its best estimates of any potentially uncollectible accounts. As at December 31, 2014, the balance of the Company’s allowance for doubtful accounts was nil [2013 – $6,000]. The amount written off during the year ended December 31, 2014 was $8,000 [2013 - nil and 2012 - nil].
	Liquidity Risk
	Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they are due. The Company continuously monitors actual and forecasted cash flows to ensure there is sufficient working capital to satisfy its operating requirements. Refer to note 2 for a discussion of the Company’s liquidity plans.
	Pursuant to their respective terms, accounts payables, accrued liabilities, the term loan, and the repayable leasehold improvement allowance are aged as follows (in thousands):
		2015		2016		2017		2018		2019		Thereafter
		$		$		$		$		$		$
	Accounts payable and accrued liabilities		3,867		-		-		-		-		-
	Term loan		546		728		303
	Repayable leasehold improvement allowance		461		514		574		640		714		2,766
			4,874		1,242		877		640		714		2,766

Note_7_Inventories

Note 7 - Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	7. INVENTORIES
	Inventories are comprised of the following (in thousands):
		31-Dec-14		31-Dec-13
		$		$
	Raw materials		1,212		1,155
	Work in progress		309		198
	Finished goods		535		897
			2,056		2,250
	The carrying value of inventory as of December 31, 2014 includes a write-down and a provision for expired, obsolete, and damaged inventory in the amount of $135,000 [December 31, 2013 - $60,000]. For the year ended December 31, 2014, inventory write-downs and obsolescence charges were $285,000 [2013 - $25,000; 2012 - $217,000].

Note_8_Property_Plant_and_Equi

Note 8 - Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	8. PROPERTY, PLANT AND EQUIPMENT
	Property, plant, and equipment is comprised of the following (in thousands):
				Accumulated		Net book
		Cost		amortization		value
		$		$		$
	31-Dec-14
	Office furniture and equipment		964		959		5
	Office computer equipment		434		354		80
	Laboratory furniture and equipment		585		578		7
	Laboratory computer equipment		596		509		87
	Computer software		136		101		35
	Manufacturing equipment		2,709		2,019		690
	Manufacturing molds		603		603		-
	Leasehold improvements		9,810		4,464		5,346
			15,837		9,587		6,250
	31-Dec-13
	Office furniture and equipment		964		954		10
	Office computer equipment		358		311		47
	Laboratory furniture and equipment		585		575		10
	Laboratory computer equipment		521		476		45
	Computer software		109		70		39
	Manufacturing equipment		2,472		1,801		671
	Manufacturing molds		603		603		0
	Leasehold improvements		9,800		3,803		5,997
			15,412		8,593		6,819
	The following table shows depreciation expense allocated by type of cost (in thousands):
	Years ended December 31,	2014		2013		2012
	Cost of sales		628		614		676
	Research and development		241		252		307
	General and administrative		66		73		91
	Sales and marketing		59		53		69
			994		992		1,143
	As at December 31, 2014, $187,000 [2013 - $4,000] of manufacturing equipment was in the validation phase and not ready for use and therefore has not been depreciated.

Note_9_Accounts_Payable_and_Ac

Note 9 - Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	9. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
	Accounts payable and accrued liabilities comprise (in thousands):
		31-Dec-14		31-Dec-13
		$		$
	Trade accounts payable		1,624		1,232
	Employee related accounts payable and accrued liabilities		1,307		913
	Royalties		287		172
	Other accrued liabilities		649		410
			3,867		2,727
	Accounts payable and accrued liabilities include $15,000 of additions to property, plant, and equipment as at December 31, 2014. This amount has been excluded from cash used in investing activities respectively on the consolidated statements of cash flows for the year ended December 31, 2014, as the cash had not been disbursed. Consequently, it has also been excluded from cash used in operating activities.

Note_10_Lease_Inducements

Note 10 - Lease Inducements	12 Months Ended
	Dec. 31, 2014
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	10. LEASE INDUCEMENTS
	Lease agreements entered into by the Company for its offices provides for lease inducements to be provided by the landlord to the Company, which are summarized as follows (in thousands):
		31-Dec-14		31-Dec-13
		$		$
	Current Portion
	Rent-free inducement [i]		54		55
	Non-repayable leasehold improvement allowance [ii]		115		115
			169		170
	Repayable leasehold improvement allowance [iii]		461		413
	Total Current Portion		630		583
	Long-Term Portion
	Rent-free inducement [i]		385		439
	Non-repayable leasehold improvement allowance [ii]		812		927
			1,197		1,366
	Repayable leasehold improvement allowance [iii]		5,208		5,669
	Total Long-Term Portion		6,405		7,035
	Total		7,035		7,618
	The lease inducements disclosed on the consolidated balance sheets as a result of these benefits is comprised of the following:
	[i]      In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense Amortization expense for the year ended December 31, 2014 amounted to $54,000 [2013 - $54,000; 2012 - $54,000].
	[ii]      The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the year ended December 31, 2014 amounted to $115,000 [2013 - $115,000; 2012 - $115,000].
	[iii]     The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the year ended December 31, 2014 amounted to $413,000 [2013 - $370,000; 2012 - $332,000], respectively. Interest payments for the year ended December 31, 2014 amounted to $649,000 [2013 - $691,000; 2012 - $730,000].
	To secure the lease, the Company is maintaining a security deposit with the landlord in the form of an irrevocable letter of credit in the amount of $871,000 collateralized by a term deposit with a market value of $871,000 that is presented as part of restricted deposits in the long-term asset section of the balance sheets.

Note_11_Term_Loan

Note 11 - Term Loan	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Long-term Debt [Text Block]	11. TERM LOAN
	On February 11, 2014, the Company entered into a loan and security agreement with SVB providing for a US$2.5 million term loan. The loan is secured by substantially all of the assets of the Company. The loan included financial covenants that were later removed in an amendment (refer to discussion below). The loan also includes certain non-financial covenants as well as a subjective acceleration clause. Under the terms of the original loan agreement, the total proceeds of US$2.5 million were available in tranches of US$1.5 million upon closing and the remaining US$1.0 million was available at the discretion of the Company at any time prior to September 30, 2014 if the Company remained in compliance with the terms of the loan agreement. The second tranche was not drawn as of September 30, 2014. The loan matures on May 1, 2017 and bears an interest rate of Wall Street Journal Prime Rate plus 2.5% annually. Interest only payments were made until October 1, 2014 at which time, 32 equal monthly installments of principal plus accrued interest started to be made. The loan contains a voluntary prepayment option whereby the principal amount can be prepaid in whole, or in part, for a fixed fee if a prepayment is made on or before February 10, 2016. Response provided SVB with 52,796 warrants with an exercise price of $1.831 per warrant and a term of 10 years. These warrants were measured at their fair market value using the Black-Scholes model on the date of the grant using the following assumptions: Risk free interest rate: 2.04%; Expected dividend yield: 0.0%; Expected life: 10.0 years; Expected volatility: 110%. The estimated fair value of the warrants was $73,000 and was recorded as a debt discount that is being amortized into income over the term of the loan using the effective interest method. In addition, there were $224,000 of fees related to the original term loan that are also being amortized over the term of the loan using the effective interest method.
	The Company made all contractual interest and principal payments during 2014, but in several months late in 2014, the Company did not meet certain financial covenants. Upon such covenant breaches, SVB was contractually entitled to declare a default and request immediate repayment of the outstanding loan amount. The Company entered into a forbearance agreement with SVB on September 30, 2014 and November 3, 2014 where SVB granted a forbearance under which it agreed not to exercise its rights in respect of these breaches. On December 15, 2014, the Company entered into an amendment to the original loan agreement with SVB. Under the amendment, SVB agreed to continue to advance the remaining outstanding principal of US$1.4 million for the same term and interest rate under the original agreement. In addition, SVB waived its rights in respect of the breaches discussed above and removed any future financial covenants. Interest only payments would be made until April 1, 2015, at which time, 26 equal monthly installments of principal plus accrued interest would be made through to maturity on May 1, 2017. In addition, the Company will pay an additional final payment of up to 4% of the outstanding principal advanced upon repayment. Response provided SVB with 54,905 warrants with an exercise price of $1.00 per warrant and a term of 10 years. These warrants were measured at their fair market value using the Black-Scholes model on the date of the grant using the following assumptions: Risk free interest rate: 1.57%; Expected dividend yield: 0.0%; Expected life: 10.0 years; Expected volatility: 112%. The estimated fair value of the warrants was $40,000 and was recorded as an additional debt discount that is being amortized into income over the remaining term of the loan using the effective interest method. There were $9,000 of fees related to the modification of the term loan that are being amortized over the remaining term of the loan using the effective interest method.
	Amortization of the deferred financing costs for the year ended December 31, 2014 was $99,000 (2013 and 2012 – nil) and amortization of the debt discount for the year ended December 31, 2014 was $34,000 (2013 and 2012 – nil). Both of these amounts are included in interest expense and amortization of deferred financing costs and debt discount on the consolidated statements of loss and comprehensive loss.
	The term loan is comprised of the following amounts (in thousands):
		31-Dec-14			31-Dec-13
		$			$
	Current portion of term loan		546			-
	Current portion of unamortized debt discount		(52	)		-
	Current portion of term loan, net debt discount		494			-
	Long-term portion of term loan		1,031			-
	Long-term portion of unamortized debt discount		(27	)		-
	Long-term portion of term loan, net debt discount		1,004			-
	Total		1,498			-
	Future principal payments for the term loan as of December 31, 2014, are as follows (in thousands):
	December 31,	$
	2015		546
	2016		728
	2017		303
	2018		-
	2019		-
	Thereafter		-
	Total		1,577

Note_12_Share_Capital_and_Addi

Note 12 - Share Capital and Additional Paid-in Capital	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	12. SHARE CAPITAL AND ADDITIONAL PAID-IN CAPITAL
	[a]     Authorized - Unlimited common shares without par value.
	[b]      Issued
	2014 Private Placement
	On December 12, 2014, the Company closed a private placement with Joinstar related entities consisting of 1,800,000 common shares at a price of $1.21 per share for total gross proceeds of $2,178,000. The net proceeds were $2,024,000 after deduction of $154,000 of financing costs.
	2013 Private Placement
	On November 7, 2013, the Company’s shareholders approved a brokered and non-brokered private placement of 1,273,117 subscription receipts (the “Subscription Receipts”) at a price of $2.45 for aggregate gross proceeds of $3.1 million (the “Private Placement”). Each Subscription Receipt automatically entitles the holder to receive one unit. Each unit consists of one common share and one-half of one warrant to purchase one common share. Each whole warrant has a term of 36 months and an exercise price of $3.58.
	The net proceeds were $2.8 million after deduction of $388,000 of financing costs. Of these net proceeds, $2.1 million was allocated to common shares and $677,000 was allocated to warrants.
	[c]      Stock option plan
	At the Annual General Meeting held September 3, 2008, the Company’s shareholders approved a new stock option plan (“2008 Plan”). Under the plan, the Company may grant options to purchase common shares in the Company to employees, directors, officers and consultants of the Company. The exercise price of the options is determined by the Board but is equal to the fair market value of the common shares at the grant date. The Company estimates the fair value of options on the date of the grant. The options vest over the requisite service period in accordance with terms as determined by the Board, typically over four years. Stock options expire no later than ten years from the date of grant.
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders’ approved a change to the Company’s 2008 stock option plan permitting the maximum shares authorized to be issued under the plan to be up to 20% of the issued and outstanding common shares outstanding at any point in time.
	Of the 1,951,912 stock options authorized for grant under the 2008 Plan as at December 31, 2014, options for 1,007,629 shares were outstanding and 944,283 stock options were available for future grant.
	The following assumptions were used to estimate the fair value of options granted during the years ended December 31, 2014, 2013, and 2012 using a Black-Scholes option-pricing model:
	Year ended December 31,		2014				2013				2012
	Risk-free interest rates			1.98	%			1.69	%			1.68	%
	Expected dividend yield			0	%			0	%			0	%
	Expected life (in years)			5.96				5.76				5.95
	Expected volatility			126	%			123	%			113	%
	Fair value per stock option		$	1.2			$	2.63			$	1.57
	The expected volatility reflects the assumption that the historical volatility of common stock of the Company over a period similar to the expected life of the options is indicative of future trends. The Company estimates the risk-free interest rate using the Bank of Canada bond yield with a remaining term equal to the expected life of the option. The Company uses the simplified method for estimating the stock option term for stock option grants during the year ended December 31, 2014 as the Company has determined that the stock options are “plain vanilla” and historical share option exercises do not apply as the vesting term and contractual lives have significantly changed from those stock options exercised previously.
	The total fair value of options vested during the fiscal 2014, 2013, and 2012 years was $357,000, $605,000, and $355,000 respectively.
	Total aggregate intrinsic value represents the pre-tax intrinsic value, based on the Company’s closing stock price as of December 31, 2014, that would have been received by the option holders had all option holders exercised their stock options as of that date. The intrinsic value of the options outstanding as at December 31, 2014, 2013, 2012 was nil, $31,000, and $2,000 respectively. There were no stock option exercises during the years ended December 31, 2014, 2013, and 2012.
	At December 31, 2014, the following stock options were outstanding:
		Range of exercise price				Number of				Weighted average				Weighted		Number of		Weighted
						shares under				remaining				average		options currently		average
						option				contractual life				exercise price		exercisable		exercise price
		$				#				(years)				$		#		$
			0.88				115,790				9.88				0.88		-		-
			1.02  -  1.80				314,454				8.46				1.46		111,037		1.4
			2.2				388,861				7.26				2.2		348,122		2.2
			3.00  -  3.10				186,700				8.22				3.1		159,877		3.1
			6.80  -  8.20				1,824				1.12				7.7		1,496		7.89
			0.88  - 8.20				1,007,629				8.1				1.99		620,532		2.3
	The options expire at various dates from December 1, 2015 to November 13, 2024.
	Stock option transactions and the number of stock options outstanding are summarized as follows:
			Number of optioned				Weighted average
			common shares				exercise price
			#				$
	Balance, December 31, 2012			989,064				1.98
	Options granted			215,170				3.03
	Options forfeited			(68,926	)			2.32
	Options expired			(4,680	)			21.94
	Balance at December 31, 2013			1,130,628				2.08
	Options granted			506,780				1.36
	Options forfeited			(629,194	)			1.62
	Options expired			(585	)			23
	Balance, December 31, 2014			1,007,629				1.99
	[d]      Restricted share unit plan
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new restricted share unit plan (“RSU Plan”). Under the plan, the Company may grant Restricted Share Units (“RSUs”) to employees, directors, and eligible consultants which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of vested RSUs multiplied by the then current market value of the RSUs. The fair market value of the RSUs is determined based upon the number of RSUs granted and the quoted closing price of the Company’s stock on the trading day immediately preceding the date of determination. The duration of the vesting period and other vesting terms applicable to the grant of the RSUs shall be determined by the Board.
			Number				Weighted average
			of RSUs				exercise price
			#				$
	Balance at December 31, 2012			-				-
	RSUs granted			118,439				1.89
	RSUs converted to common shares			(20,114	)			1.93
	Balance, December 31, 2013			98,325				1.88
	RSUs granted			126,688				1.27
	RSUs converted to common shares			(88,665	)			1.75
	Balance, December 31, 2014			136,348				1.39
	The RSUs that were granted during the years ended December 31, 2014 and 2013 were to settle a director compensation liability that was recorded in accounts payable and accrued liabilities on the consolidated balance sheets. The $160,000 of director fees paid by RSUs during the year ended December 31, 2014 (2013 - $223,000) were excluded from the change in accounts payable and accrued liabilities on the statement of cash flows.
	Of the 243,989 RSUs authorized for grant under the RSU Plan as at December 31, 2014, 107,641 RSUs are available for grant.
	[e]     Deferred share unit plan
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new non-employee director deferred share unit plan (“DSU Plan”). A Deferred Share Unit (“DSU”) is a right granted to non-employee directors which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of DSUs multiplied by the then current market value of the DSUs. The fair market value of the DSU’s is determined based upon the number of DSUs granted and the quoted price of the Company’s stock on the trading day immediately preceding the determination date. The duration of the vesting period and other vesting terms applicable to the grant of the DSU’s shall be determined by the Board.
	Of the 243,989 DSUs authorized for grant under the DSU Plan as at December 31, 2014, all are available for grant.
[f] Stock-based compensation
The following table shows stock-based compensation allocated by type of cost (in thousands):
Year ended December 31,		2014				2013				2012
		$				$				$
Cost of sales			36				29				27
Research and development			45				44				48
General and administrative			259				551				528
Sales and marketing			41				36				11
			381				660				614
As of December 31, 2014, the total unrecognized compensation expense related to stock options granted amounts to $306,000, which is expected to be recognized over a weighted average service period of 2.0 years.
[g] Common share purchase warrants
At December 31, 2014, there were 86,865,691 warrants outstanding to purchase shares of common stock, with expiry dates ranging from November 7, 2015 to December 15, 2024. Of the total 86,865,691 warrants outstanding, 86,103,744 warrants (the warrants related to the 2011 financing) entitle the holder thereof to purchase 1/20th of a common share of the Company at a price of $1.492 per whole common share; 636,557 warrants (the private placement warrants) entitle the holder thereof to purchase one common share of the Company at a price of $3.58 per common share; 17,689 warrants (the agent warrants) entitle the holder thereof to purchase one common share of the Company at a price of $2.45 per common share, 52,796 warrants entitle the holder thereof to purchase one common share of the Company at a price of $1.831 per common share, and 54,905 warrants entitle the holder thereof to purchase one common share of the Company at a price of $1.00 per common share.
Common share purchase warrant transactions are summarized as follows:
		Number of				Weighted average
		warrants				exercise price
		#				$
Balance, December 31, 2012			89,976,289				0.0746
Warrants issued			654,246				3.55
Exercise of warrants			(3,872,545	)			0.0746
Balance, December 31, 2013			86,757,990				0.1008
Warrants issued			107,701				1.4074
Balance, December 31, 2014			86,865,691				0.1024
The estimated fair value of the warrants related to the 2011 financing is reassessed at each balance sheet date using the Black-Scholes option pricing model. The following assumptions were used to value the warrants on the following balance sheet dates:
		2014				2013
Risk-free interest rates			1	%			1.1	%
Expected dividend yield			0	%			0	%
Expected life (in years)			2				3
Expected volatility			111	%			140	%
Fair value of warrant		$	0.0355			$	0.061
[h]     Earnings per common share
Basic net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding using the treasury stock method. Dilutive potential common shares outstanding include outstanding warrants, stock options, and restricted share units.
86,865,691 warrants, 1,007,629 stock options and 136,348 restricted share units have been excluded from the computation of diluted earnings per share for the year ended December 31, 2014 as the Company has incurred a net loss during the year and their inclusion would be anti-dilutive to the loss per share (2013 – 86,757,990 warrants, 1,130,628 stock options and 98,325 restricted share units were excluded).

Note_13_Related_Party_Transact

Note 13 - Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	13. RELATED PARTY TRANSACTIONS
	[a] On December 12, 2014, the Company closed a private placement with Joinstar related entities consisting of 1,800,000 common shares at a price of $1.21 per share for total net proceeds of $2,024,000. Upon closing, the Joinstar entities became a principal owner of the Company with a combined ownership of 18.4% of the outstanding common shares as at December 31, 2014.
	[b] On October 22, 2014, the Company received the first milestone payment of US$560,000 earned under the Technology Development Agreement signed with Joinstar. This upfront payment is being recognized into income over development period and for the year ended December 31, 2014, $186,000 was recognized (2013 and 2012 – nil). These development fees are included under collaborative revenue in the consolidated statements of loss and comprehensive loss. The unrecognized portion of the development fees are included under deferred revenue – current portion on the consolidated balance sheet.
	[c] On November 7, 2013, the Company’s shareholders approved the Private Placement described in note 12[b]. Of the 1,273,117 subscription receipts issued, 816,325 subscription receipts were issued to a group of investment funds controlled by OrbiMed Advisors, LLC (“OrbiMed”), the Company’s majority shareholder. Upon conversion of the subscription receipts, 816,325 common shares and 408,162 warrants were issued. In connection with the Private Placement, the Company incurred and paid legal costs of $53,000 on behalf of OrbiMed.
	[d] The Company incurred consulting fees to a director of $174,000 for the year ended December 31, 2012. There were no such fees incurred during the year ended December 31, 2014 and 2013. These amounts have been paid during the year and no amount is included in accounts payable and accrued liabilities as at December 31, 2014 and 2013. These consulting fees were included in general and administrative expenses in the consolidated statement of loss and comprehensive loss.

Note_14_Income_Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. INCOME TAXES
	At December 31, 2014 the Company had approximately $60.0 million [2013 - $60.9 million] of non-capital loss carry forwards, approximately $3.1 million [2013 - $2.7 million] of federal investment tax credits and approximately $794,000 [2013 - $679,000] of provincial investment tax credits available to reduce taxable income and taxes payable for future years. These losses and investment tax credits expire as follows (in thousands):
	Year of Expiry	Provincial investment tax credit			Federal investment tax credits			Non-capital loss carryforwards
	2015		58			-			6,880
	2016		142			-			-
	2017		205			-			-
	2018		198			151			-
	2019		56			227			-
	2020		-			430			-
	2021		28			384			-
	2022		53			233			-
	2023		20			168			-
	2024		34			36			-
	2025		-			105			-
	2026		-			256			7,669
	2027		-			370			8,560
	2028		-			357			4,107
	2029		-			101			7,217
	2030		-			-			9,266
	2031		-			50			5,796
	2032		-			96			3,887
	2033					35			3,166
	2034					61			3,488
			794			3,060			60,036
	In addition, the Company has unclaimed tax deductions of approximately $12.5 million [2013 - $11.8 million] related to scientific research and experimental development expenditures available to carry forward indefinitely to reduce taxable income of future years and other deductible temporary differences of approximately $19.8 million [2013 - $17.9 million].
	Significant components of the Company’s deferred tax assets are shown below (in thousands):
		2014			2013
		$			$
	Future Tax Assets:
	Book amortization in excess of tax capital cost allowance		2,647			2,296
	Non-capital loss carry forwards		15,609			15,222
	Research and development deductions and credits		6,336			6,001
	Share issue costs		113			169
	Unearned revenue		227			22
	Free rent liability		110			124
	Non-repayable lease inducements		232			260
	Repayable lease inducements		1,417			1,521
	Other		86			83
	Total future tax assets		26,777			25,698
	Valuation allowance		(26,777	)		(25,698	)
	Net future tax assets		-			-
	The potential income tax benefits relating to these deferred tax assets have not been recognized in the consolidated financial statements as their realization does not meet the requirements of “more likely than not” under the liability method of tax accounting. Accordingly, a valuation allowance has been recorded and no deferred tax assets have been recognized as at December 31, 2014 and 2013.
	The reconciliation of income tax attributable to operations computed at the statutory tax rate to income tax expense, using a 26.0% [2013 – 25.0%; 2012 – 25.0%] statutory tax rate is as follows (in thousands):
		2014			2013			2012
		$			$			$
	Income tax recovery at statutory rates		(526	)		(1,500	)		(1,318	)
	Tax expense of other tax jurisdictions		68			41			-
	Expenses not deductible for tax purposes		(923	)		691			247
	Non-capital losses for which no benefit has been recognized		907			755			1,082
	Other temporary differences for which no benefit has been recognized		542			54			(11	)
	Total income tax expense		68			41			-
	The reconciliation of the unrecognized tax benefits of uncertain tax positions is as follows (in thousands):
		$
	Balance at December 31, 2012		44
	Balance at December 31, 2013		44
	Additions based on tax positions related to the current year		-
	Balance at December 31, 2014		44
	As of December 31, 2014, unrecognized benefits of approximately $44,000, if recognized, would affect the Company’s effective tax rate, and would reduce the Company’s deferred tax assets. Interest and penalties related to the unrecognized tax benefits that are accrued in the Company’s balance sheets as at December 31, 2014 were $24,000.
	The Company is subject to taxes in Canada, the United States of America, and China. The tax years which remain subject to examination as of December 31, 2014 for Canada include 2008 to 2014. The tax years which remain subject to examination as of December 31, 2014 for the United States of America and China include 2013 to 2014.

Note_15_Commitments

Note 15 - Commitments	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Commitments Disclosure [Text Block]	15. COMMITMENTS
	[a]     License agreements
	The Company entered into a non-exclusive license agreement, effective July 2005, as amended June 2008, to use and sublicense certain technology (“Technology”) for one of the Company’s cardiac tests. In consideration for these rights, the Company paid a non-refundable license issuance fee of $2.0 million in the first two years after execution of the agreement and is required to pay quarterly royalties on the sale of products that incorporate the Technology. For the year ended December 31, 2014, the Company incurred an expense of $628,000 [2013 - $616,000; 2012 - $634,000] for royalties. Royalty and license fees incurred are included in cost of sales
	[b]     Supply agreement
	The Company entered into a supply agreement, effective September 2003 for certain reagents for the Company’s RAMP® West Nile Virus Test. In addition to paying for the reagent purchased, the Company is required to pay the supplier semi-annual royalties equal to 10% of net revenue generated from the sale of the Company’s RAMP® West Nile Virus Test. The initial term of the agreement was three years from the effective date and is automatically renewed for successive periods of one year until either party terminates the agreement. For the year ended December 31, 2014, the Company incurred an expense of $49,000 [2013 - $56,000; 2012 - $42,000] for royalties to the supplier. These royalties are included in cost of sales.
	[c]     Lease agreements
	[i]     The Company entered into a long-term agreement to lease a single tenant 46,000 square foot facility to house all of the Company’s operations beginning March 2008. Rent is payable from February 1, 2008 to January 31, 2023. The Company is required to pay the landlord total gross monthly payments of approximately $173,000, which is comprised of base rent, administrative and management fees, estimated property taxes and repayments of the repayable leasehold improvement allowance [note 10[iii]].
	[ii]     The Company had entered into a lease agreement for office space for its Representative Office in China on November 18, 2012 where the Company was required to make monthly payments of approximately $5,000 for base rent and management fees. The lease agreement expired on September 17, 2014. The Company entered into a new lease agreement for new office space that expires on September 9, 2015. The Company is required to make monthly payments of approximately $8,000 for base rent and management fees under the new lease agreement.
	[ii]     The Company has entered into operating leases for administrative equipment.
	[iii]     The minimum annual cost of lease commitments is estimated as follows (in thousands):
		Premise		Equipment		Total
	December 31,	$		$		$
	2015		2,074		19		2,093
	2016		2,102		10		2,112
	2017		2,130		1		2,131
	2018		2,160		-		2,160
	2019		2,190		-		2,190
	Thereafter		6,949		-		6,949
			17,605		30		17,635
	For the year ended December 31, 2014, $802,000 [2013 - $807,000; 2012 - $779,000] was incurred for expenses related to base rent, administrative and management fees and estimated property taxes offset by amortization of both the rent-free inducement [note 10[i]] and non-repayable leasehold improvement allowance [note 10[ii]]. These expenses are allocated to cost of sales, research and development, general and administrative, and sales and marketing expenses.
	[d] Purchase Commitments
	As at December 31, 2014, the Company has outstanding purchase commitments to purchase inventory, equipment, and other services. The purchase commitments are summarized as follows (in thousands):
	December 31,	$
	2015		1,163
	2016		133
	2017		175
	2018		195
	2019		150
	Thereafter		-
			1,816
	[e] Indemnification of directors and officers
	Under the Articles of the Company, applicable law and agreements with its directors and officers, the Company, in circumstances where the individual has acted legally, honestly and in good faith, may, or is required to indemnify its directors and officers against certain losses.  The Company's liability in respect of the indemnities is not limited. The maximum potential of the future payments is unlimited. However, the Company maintains appropriate liability insurance that limits the exposure and enables the Company to recover any future amounts paid, less any deductible amounts pursuant to the terms of the respective policies, the amounts of which are not considered material.
	[f] Indemnification of third parties
	The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnifications generally require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims for damages arising from these transactions. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount that it could be required to pay. To date, the Company has not made any indemnification payments under such agreements and no amount has been accrued in these consolidated financial statements with respect to these indemnification obligations.

Note_16_Segmented_Information

Note 16 - Segmented Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	16. SEGMENTED INFORMATION
	The Company operates primarily in one business segment, the research, development, commercialization and distribution of diagnostic technologies, with primarily all of its assets and operations located in Canada. The Company’s revenues are generated from product sales primarily in the United States, Europe, Asia and Canada. Expenses are primarily incurred from purchases made from suppliers in Canada and the United States.
	Customers that represent a concentration risk are those whose outstanding receivable is 10% or greater than the total balance or those customers who represent 10% or greater of our total revenue. Refer to note 6 for a discussion of concentration risk in relation to outstanding receivables. For the year ended December 31, 2014, $6.3 million (58%) in product sales was generated from two customers of which one customer represented 33% and the other customer represented 25%[2013 - $5.8 million (50%) from two customers of which one customer represented 36% and the other customer 14%; 2012 - $7.7 million (66%) from two customers of which one customer represented 48% and the other customer 18%].
	Product sales by customer location were as follows (in thousands):
	Years ended December 31,	2014		2013		2012
		$		$		$
	China		6,905		7,153		7,748
	United States		1,246		1,670		1,124
	Asia (excluding China)		512		807		824
	Europe		1,304		1,121		1,081
	Canada		73		35		30
	Other		788		745		943
	Total		10,828		11,531		11,750
	Product sales by type of product were as follows (in thousands):
	Years ended December 31,	2014		2013		2012
		$		$		$
	Cardiovascular		9,785		10,056		10,798
	Infectious Diseases		163		450		173
	Biodefense products		360		403		317
	West Nile Virus (Environmental)		520		622		462
	Total		10,828		11,531		11,750

Note_17_Subsequent_Events

Note 17 - Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	17. SUBSEQUENT EVENTS
	On February 16, 2015, the Company announced that it had signed the definitive Collaboration Agreement with Joinstar to support the co-development by Response and Joinstar of components and assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. As a result, the Company has earned the second milestone of US$720,000 in the Collaboration Agreement with Joinstar. Concurrently, the companies have entered into a definitive Supply Agreement whereby Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates
	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Areas of significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, recoverability of long-lived assets and provisions for doubtful accounts, inventory obsolescence, inventory valuation, warranty accruals, and going concern assessments. Actual results could differ from those estimates.
Liquidity Disclosure [Policy Text Block]	Certain Significant Risks and Uncertainties
	The Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material adverse effect on its future financial position or results of operations: continued regulatory compliance or regulatory changes; the ability to develop new products and services that are accepted in the marketplace; competition, including, but not limited to, pricing and products or product features and services; litigation or other claims; the adequate and timely sourcing and manufacturing of inventories; and the hiring, training and retention of key employees.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash equivalents
	The Company considers all highly liquid investments with an original maturity of 90 days or less, when acquired, to be cash equivalents.
Inventory, Policy [Policy Text Block]	Inventories
	Raw material, finished goods and work in progress inventories are carried at the lower of actual cost, determined on a first-in first-out basis, and market value. The cost of finished goods and work in progress inventories includes direct materials, direct labour and applicable overhead. The Company writes down its inventory balances for estimates of excess and obsolete amounts. These write-downs are recorded as a component of cost of sales. At the point of the write-down, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long Lived Asset Impairment
	Long-lived assets to be held and used by the Company are periodically reviewed to determine whether any events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. For long-lived assets to be held and used, the Company bases its evaluation on impairment indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements, as well as other external market conditions or factors that may be present. In the event that facts and circumstances indicate that the carrying amount of an asset may not be recoverable and an estimate of future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss will be recognized for the difference between the carrying value and the fair value.
Lease, Policy [Policy Text Block]	Leases
	Leases are classified as either capital or operating leases. Leases that transfer substantially all the benefits and risks of ownership of the property to the Company are accounted for as capital leases. All other leases are accounted for as operating leases wherein rental payments are expensed in a manner that results in the total rent payments being recognized on a straight-line basis over the term of the lease.
Deferred Charges, Policy [Policy Text Block]	Deferred lease inducements
	Lease inducements arising from rent-free inducements and non-repayable leasehold improvement allowances received from the landlord are being amortized over the term of the lease on a straight-line basis.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition
	Product sales are recognized when legal title passes to distributors or customers, the sales price is fixed and determinable, collection of the resulting receivables is reasonably assured and no uncertainties with regard to customer acceptance exist. Sales are recorded net of discounts and sales returns.
	When arrangements include multiple elements, we use objective evidence of fair value to allocate revenue to the elements, and recognize revenue when the criteria for revenue recognition have been met for each element, in accordance with authoritative guidance on multiple-element arrangements.
	Upfront fees from collaborative research arrangements that are non-refundable, require the ongoing involvement of the Company and are directly linked to specific milestones are deferred and amortized into income as services are rendered. Upfront fees from collaborative research arrangements that are non-refundable, require the ongoing involvement of the Company and are not directly linked to specific milestones are deferred and amortized into income on a straight-line basis over the term of ongoing development. Upfront fees from collaborative research arrangements that are refundable are deferred and recognized once the refundable period has lapsed.
Receivables, Policy [Policy Text Block]	Accounts Receivable
	For product sales, the Company typically invoices its customers at shipment for the sales order value of products shipped. For contract revenue, invoicing occurs based upon the terms of the specific research contract, typically one month in arrears for services rendered and any other allowable direct costs. Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company does not have any off-balance sheet credit exposure related to any of its customers.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Allowance for Doubtful Accounts
	The Company evaluates the collectability of accounts receivable based on a combination of factors. In cases where the Company becomes aware of circumstances that may impair a specific customer’s ability to meet its financial obligations subsequent to the original sale, the Company will record an allowance against amounts due, and thereby reduce the net recognized receivable to the amount the Company reasonably believes will be collected. For all other customers, the Company recognizes an allowance for doubtful accounts based on the length of time the receivables are past due and consideration of other factors such as industry conditions, the current business environment and its historical experience.
Deferred Charges, Deferred Financing Costs [Policy Text Block]	Deferred Financing CostsThe Company capitalizes incremental costs directly attributable to obtaining debt. The deferred financing costs are subsequently amortized using the effective interest rate method to interest expense over the contractual life of the debt. Under a modification to a debt arrangement, only the incremental costs directly paid to the lender are capitalized and amortized over the contractual life of the debt. All incremental costs paid to third parties are expensed when incurred and are included in general and administrative expenses on the consolidated statements of loss and comprehensive loss.
Standard Product Warranty, Policy [Policy Text Block]	Warranty accrual
	The Company offers a standard limited warranty on its products. The Company estimates costs that may be incurred under its warranty program as liabilities at the time the products are sold. Factors that affect the Company’s warranty liability include the number of units sold, anticipated rate of warranty claims, and costs per claim, which require management to make estimates about future costs. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. The initial recognition of and subsequent adjustments to the warranty accrual are recorded to cost of sales.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs
	Research and development costs are expensed as incurred and include expenses associated with new product research and regulatory activities.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs
	Shipping and handling costs are included in cost of revenues and are recognized as a period expense during the period in which they are incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-based compensation
	The Company uses the fair value method of accounting for all stock-based awards for non-employees and for all stock-based awards to employees that were granted, modified or settled since January 1, 2003. The fair value of stock options is determined using the Black-Scholes option-pricing model, which requires certain assumptions, including future stock price volatility, estimated forfeiture rates and expected time to exercise. Stock-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those stock-based awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Changes to any of these assumptions could produce different fair values for stock-based compensation. The expense is amortized on a straight-line basis over the graded vesting period.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, plant and equipment
	Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives using the straight-line method as follows:
	Office and laboratory furniture and equipment (years)	5
	Office and laboratory computer equipment (years)	3
	Computer software (years)	2
	Manufacturing equipment (years)	5 – 7
	Manufacturing molds (years)	2
	Leasehold improvements	Initial term of lease
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted deposits
	Restricted deposits consist of long-term deposits pledged as security as part of certain contractual obligations. The interest earned on these deposits is recorded in interest income on the consolidated statements of loss and comprehensive loss.
Derivatives, Policy [Policy Text Block]	Financial Instruments
	Financial instruments include cash, cash equivalents, receivables, restricted deposits, accounts payable, accrued and other liabilities, term loan, warrant liability, and the repayable leasehold improvement allowance. The Company has classified restricted deposits as held-to-maturity. Trade receivables and other receivables are classified as loans and receivables. Accounts payable, accrued and other liabilities, term loan, warrant liability and the repayable leasehold improvement allowance are classified as other financial liabilities.
	Held-for-trading financial instruments are initially measured at fair value with subsequent changes in fair value recorded to net income. Held-to-maturity investments are measured at amortized cost using the effective interest method with changes in amortized cost recorded to net income. Loans and receivables and other financial liabilities are initially measured at amortized cost with subsequent changes in amortized cost recorded to net income. Transaction costs (except for transaction costs related to held-for-trading financial instruments, which are expensed as, incurred) are included in the carrying amounts of financial instruments as they are carried on the consolidated balance sheet.
Warrants Policy [Policy Text Block]	WarrantsThe Company accounts for warrants, issued in the 2011 rights offering, pursuant to the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock. The Company classifies warrants on the consolidated balance sheet as a liability that is revalued at each balance sheet date subsequent to the initial issuance. Determining the appropriate fair-value model, and calculating the fair value of warrants requires considerable judgment, including estimating stock price volatility and expected warrant life. The computation of expected volatility was based on the historical volatility of shares of the Company’s common stock for a period that coincides with the expected life of the warrants. A small change in the estimates used may have a relatively large change in the estimated valuation. The Company uses the Black-Scholes pricing model to value the warrants. Changes in the fair market value of the warrants are reflected in the consolidated statement of loss as Unrealized (gain)/loss on revaluation of warrant liability
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation
	Monetary items denominated in foreign currencies are translated into Canadian dollars using exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expense items are translated at the average exchange rate for the period. Foreign exchange gains and losses are included in the determination of loss for the year.
Income Tax, Policy [Policy Text Block]	Income taxes
	The Company accounts for income taxes using the liability method of tax allocation. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases. Deferred income tax assets and liabilities are measured using substantively enacted income tax rates expected to apply to taxable income in the years in which temporary differences are expected to reverse. The effect on deferred income tax assets and liabilities of a change in substantively enacted rates is included in earnings in the period that includes the substantive enactment date. Deferred income tax assets, net of a valuation allowance, are recorded in the consolidated financial statements if realization is considered more likely than not.
	The Company accounts for uncertain tax positions using a “more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company includes interest and penalties related to gross unrecognized tax benefits in the provision for income taxes.
Scientific Research and Development Tax Credits Policy [Policy Text Block]	Scientific Research and Development Tax CreditsThe benefits of tax credits for scientific research and development expenditures are recognized in the year the qualifying expenditure is made provided there is reasonable assurance of recoverability. The tax credits recorded are based on the Company’s estimates of amounts expected to be recovered and are subject to audit by taxation authorities. All qualifying expenditures are eligible for non-refundable tax credits only.
Earnings Per Share, Policy [Policy Text Block]	Loss per common share
	Basic loss per common share is calculated using the weighted average number of common shares outstanding during the year, excluding contingently issuable shares. Diluted loss per common share is computed in accordance with the treasury stock method that uses the weighted average number of common shares outstanding during the period. The effect of potentially issuable common shares from outstanding stock options and outstanding warrants is anti-dilutive for all periods presented.
Segment Reporting, Policy [Policy Text Block]	Segment Information
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its senior management team. The Company has one operating segment that is dedicated to the manufacture and sale of RAMP® tests. In note 16, the Company discloses information about Products and Services, Geographic Areas, and Major Customers.

Note_3_Significant_Accounting_1

Note 3 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Property, Plant, and Equipment Useful Lives [Table Text Block]	Office and laboratory furniture and equipment (years)	5
	Office and laboratory computer equipment (years)	3
	Computer software (years)	2
	Manufacturing equipment (years)	5 – 7
	Manufacturing molds (years)	2
	Leasehold improvements	Initial term of lease

Note_5_Fair_Value_Measurements1

Note 5 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value, by Balance Sheet Grouping [Table Text Block]			Level 1			Level 2			Level 3		Total
	Liabilities		$			$			$		$
	Warrant Liability			-			-			1,249		1,249
			Level 1			Level 2			Level 3		Total
	Liabilities		$			$			$		$
	Warrant Liability			-			-			5,251		5,251
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]			Balance at								Balance at
			31-Dec-13			Unrealized loss			Exercise of Warrants		31-Dec-14
	Warrant Liability			5,251			(4,002	)		-		1,249
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]		Valuation Technique	Unobservable Input	As at December 31, 2014	As at December 31, 2013
	Warrant Liability	Option Model	Stock Price Volatility	106%	140%

Note_6_Financial_Instruments_T

Note 6 - Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Aging of Financial Instrument Liabilites [Table Text Block]		2015		2016		2017		2018		2019		Thereafter
		$		$		$		$		$		$
	Accounts payable and accrued liabilities		3,867		-		-		-		-		-
	Term loan		546		728		303
	Repayable leasehold improvement allowance		461		514		574		640		714		2,766
			4,874		1,242		877		640		714		2,766

Note_7_Inventories_Tables

Note 7 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]		31-Dec-14		31-Dec-13
		$		$
	Raw materials		1,212		1,155
	Work in progress		309		198
	Finished goods		535		897
			2,056		2,250

Note_8_Property_Plant_and_Equi1

Note 8 - Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]				Accumulated		Net book
		Cost		amortization		value
		$		$		$
	31-Dec-14
	Office furniture and equipment		964		959		5
	Office computer equipment		434		354		80
	Laboratory furniture and equipment		585		578		7
	Laboratory computer equipment		596		509		87
	Computer software		136		101		35
	Manufacturing equipment		2,709		2,019		690
	Manufacturing molds		603		603		-
	Leasehold improvements		9,810		4,464		5,346
			15,837		9,587		6,250
	31-Dec-13
	Office furniture and equipment		964		954		10
	Office computer equipment		358		311		47
	Laboratory furniture and equipment		585		575		10
	Laboratory computer equipment		521		476		45
	Computer software		109		70		39
	Manufacturing equipment		2,472		1,801		671
	Manufacturing molds		603		603		0
	Leasehold improvements		9,800		3,803		5,997
			15,412		8,593		6,819
Depreciation Expense Allocation [Table Text Block]	Years ended December 31,	2014		2013		2012
	Cost of sales		628		614		676
	Research and development		241		252		307
	General and administrative		66		73		91
	Sales and marketing		59		53		69
			994		992		1,143

Note_9_Accounts_Payable_and_Ac1

Note 9 - Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]		31-Dec-14		31-Dec-13
		$		$
	Trade accounts payable		1,624		1,232
	Employee related accounts payable and accrued liabilities		1,307		913
	Royalties		287		172
	Other accrued liabilities		649		410
			3,867		2,727

Note_10_Lease_Inducements_Tabl

Note 10 - Lease Inducements (Tables)	12 Months Ended
	Dec. 31, 2014
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Lease Inducements [Table Text Block]		31-Dec-14		31-Dec-13
		$		$
	Current Portion
	Rent-free inducement [i]		54		55
	Non-repayable leasehold improvement allowance [ii]		115		115
			169		170
	Repayable leasehold improvement allowance [iii]		461		413
	Total Current Portion		630		583
	Long-Term Portion
	Rent-free inducement [i]		385		439
	Non-repayable leasehold improvement allowance [ii]		812		927
			1,197		1,366
	Repayable leasehold improvement allowance [iii]		5,208		5,669
	Total Long-Term Portion		6,405		7,035
	Total		7,035		7,618

Note_11_Term_Loan_Tables

Note 11 - Term Loan (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]		31-Dec-14			31-Dec-13
		$			$
	Current portion of term loan		546			-
	Current portion of unamortized debt discount		(52	)		-
	Current portion of term loan, net debt discount		494			-
	Long-term portion of term loan		1,031			-
	Long-term portion of unamortized debt discount		(27	)		-
	Long-term portion of term loan, net debt discount		1,004			-
	Total		1,498			-
Schedule of Maturities of Long-term Debt [Table Text Block]	December 31,	$
	2015		546
	2016		728
	2017		303
	2018		-
	2019		-
	Thereafter		-
	Total		1,577

Note_12_Share_Capital_and_Addi1

Note 12 - Share Capital and Additional Paid-in Capital (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year ended December 31,		2014				2013				2012
	Risk-free interest rates			1.98	%			1.69	%			1.68	%
	Expected dividend yield			0	%			0	%			0	%
	Expected life (in years)			5.96				5.76				5.95
	Expected volatility			126	%			123	%			113	%
	Fair value per stock option		$	1.2			$	2.63			$	1.57
Schedule of Share-based Compensation, Activity [Table Text Block]		Range of exercise price				Number of				Weighted average				Weighted		Number of		Weighted
						shares under				remaining				average		options currently		average
						option				contractual life				exercise price		exercisable		exercise price
		$				#				(years)				$		#		$
			0.88				115,790				9.88				0.88		-		-
			1.02  -  1.80				314,454				8.46				1.46		111,037		1.4
			2.2				388,861				7.26				2.2		348,122		2.2
			3.00  -  3.10				186,700				8.22				3.1		159,877		3.1
			6.80  -  8.20				1,824				1.12				7.7		1,496		7.89
			0.88  - 8.20				1,007,629				8.1				1.99		620,532		2.3
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]			Number of optioned				Weighted average
			common shares				exercise price
			#				$
	Balance, December 31, 2012			989,064				1.98
	Options granted			215,170				3.03
	Options forfeited			(68,926	)			2.32
	Options expired			(4,680	)			21.94
	Balance at December 31, 2013			1,130,628				2.08
	Options granted			506,780				1.36
	Options forfeited			(629,194	)			1.62
	Options expired			(585	)			23
	Balance, December 31, 2014			1,007,629				1.99
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]			Number				Weighted average
			of RSUs				exercise price
			#				$
	Balance at December 31, 2012			-				-
	RSUs granted			118,439				1.89
	RSUs converted to common shares			(20,114	)			1.93
	Balance, December 31, 2013			98,325				1.88
	RSUs granted			126,688				1.27
	RSUs converted to common shares			(88,665	)			1.75
	Balance, December 31, 2014			136,348				1.39
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year ended December 31,		2014				2013				2012
			$				$				$
	Cost of sales			36				29				27
	Research and development			45				44				48
	General and administrative			259				551				528
	Sales and marketing			41				36				11
				381				660				614
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]			Number of				Weighted average
			warrants				exercise price
			#				$
	Balance, December 31, 2012			89,976,289				0.0746
	Warrants issued			654,246				3.55
	Exercise of warrants			(3,872,545	)			0.0746
	Balance, December 31, 2013			86,757,990				0.1008
	Warrants issued			107,701				1.4074
	Balance, December 31, 2014			86,865,691				0.1024
Estimated Fair Value of Warrants Issued, Valuation Assumptions [Table Text Block]			2014				2013
	Risk-free interest rates			1	%			1.1	%
	Expected dividend yield			0	%			0	%
	Expected life (in years)			2				3
	Expected volatility			111	%			140	%
	Fair value of warrant		$	0.0355			$	0.061

Note_14_Income_Taxes_Tables

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Summary of Operating Loss Carryforwards [Table Text Block]	Year of Expiry	Provincial investment tax credit			Federal investment tax credits			Non-capital loss carryforwards
	2015		58			-			6,880
	2016		142			-			-
	2017		205			-			-
	2018		198			151			-
	2019		56			227			-
	2020		-			430			-
	2021		28			384			-
	2022		53			233			-
	2023		20			168			-
	2024		34			36			-
	2025		-			105			-
	2026		-			256			7,669
	2027		-			370			8,560
	2028		-			357			4,107
	2029		-			101			7,217
	2030		-			-			9,266
	2031		-			50			5,796
	2032		-			96			3,887
	2033					35			3,166
	2034					61			3,488
			794			3,060			60,036
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		2014			2013
		$			$
	Future Tax Assets:
	Book amortization in excess of tax capital cost allowance		2,647			2,296
	Non-capital loss carry forwards		15,609			15,222
	Research and development deductions and credits		6,336			6,001
	Share issue costs		113			169
	Unearned revenue		227			22
	Free rent liability		110			124
	Non-repayable lease inducements		232			260
	Repayable lease inducements		1,417			1,521
	Other		86			83
	Total future tax assets		26,777			25,698
	Valuation allowance		(26,777	)		(25,698	)
	Net future tax assets		-			-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		2014			2013			2012
		$			$			$
	Income tax recovery at statutory rates		(526	)		(1,500	)		(1,318	)
	Tax expense of other tax jurisdictions		68			41			-
	Expenses not deductible for tax purposes		(923	)		691			247
	Non-capital losses for which no benefit has been recognized		907			755			1,082
	Other temporary differences for which no benefit has been recognized		542			54			(11	)
	Total income tax expense		68			41			-
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]		$
	Balance at December 31, 2012		44
	Balance at December 31, 2013		44
	Additions based on tax positions related to the current year		-
	Balance at December 31, 2014		44

Note_15_Commitments_Tables

Note 15 - Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]		Premise		Equipment		Total
	December 31,	$		$		$
	2015		2,074		19		2,093
	2016		2,102		10		2,112
	2017		2,130		1		2,131
	2018		2,160		-		2,160
	2019		2,190		-		2,190
	Thereafter		6,949		-		6,949
			17,605		30		17,635
Long-term Purchase Commitment [Table Text Block]	December 31,	$
	2015		1,163
	2016		133
	2017		175
	2018		195
	2019		150
	Thereafter		-
			1,816

Note_16_Segmented_Information_

Note 16 - Segmented Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Years ended December 31,	2014		2013		2012
		$		$		$
	China		6,905		7,153		7,748
	United States		1,246		1,670		1,124
	Asia (excluding China)		512		807		824
	Europe		1,304		1,121		1,081
	Canada		73		35		30
	Other		788		745		943
	Total		10,828		11,531		11,750
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Years ended December 31,	2014		2013		2012
		$		$		$
	Cardiovascular		9,785		10,056		10,798
	Infectious Diseases		163		450		173
	Biodefense products		360		403		317
	West Nile Virus (Environmental)		520		622		462
	Total		10,828		11,531		11,750

Note_2_Basis_of_Presentation_a1

Note 2 - Basis of Presentation and Going Concern Uncertainty (Details)

12 Months Ended

15 Months Ended

60 Months Ended

0 Months Ended

0 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2014

Dec. 31, 2015

Dec. 31, 2015

Dec. 31, 2020

Dec. 31, 2020

Feb. 16, 2015

Dec. 12, 2014

Oct. 22, 2014

Oct. 15, 2014

Dec. 12, 2014

Feb. 11, 2014

Dec. 15, 2014

CAD

CAD

CAD

CAD

Warrant [Member]

Development Milestone Payments [Member]

Development Milestone Payments [Member]

Revenue Based Payments [Member]

Revenue Based Payments [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

CAD

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Subsequent Event [Member]

CAD

USD ($)

USD ($)

CAD

USD ($)

USD ($)

Scenario, Forecast [Member]

Scenario, Forecast [Member]

USD ($)

USD ($)

USD ($)

Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]

Net Income (Loss) Attributable to Parent

-2,090,000

-5,998,000

-5,281,000

Net Cash Provided by (Used in) Operating Activities

-2,281,000

-1,274,000

-4,632,000

Cash and Cash Equivalents, at Carrying Value

3,221,000

2,958,000

2,080,000

7,355,000

Retained Earnings (Accumulated Deficit)

-120,259,000

-118,169,000

Stockholders' Equity Attributable to Parent

-894,000

-1,482,000

321,000

Working Capital Deficit

772,000

Derivative Liability, Current

1,249,000

5,251,000

1,200,000

Working Capital if Excluding Warrant Liability

477,000

Shares Issued during Period in Private Placement (in Shares)

1,800,000

Sale of Stock, Price Per Share (in Dollars per share)

1.21

Proceeds from Issuance of Private Placement

2,024,000

2,055,000

0

2,024,000

Cash Proceeds from Technology Development Agreement (in Dollars)

2,130,000

720,000

560,000

560,000

Revenue Recognition, Milestone Method, Eligible to Receive (in Dollars)

2,520,000

Development Period

15 months

Commercialization Period

5 years

Term Loan, Maximum Borrowing Capacity (in Dollars)

2,500,000

Proceeds from Bank Debt (in Dollars)

1,500,000

Debt Instrument, Face Amount (in Dollars)

$1,400,000

Final Payment, Percentage of Principal

4.00%

Note_3_Significant_Accounting_2

Note 3 - Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Number of Operating Segments	1

Note_3_Significant_Accounting_3

Note 3 - Significant Accounting Policies (Details) - Property, Plant and Equipment, Estimated Useful Lives	12 Months Ended
	Dec. 31, 2014
Furniture and Fixtures [Member]
Note 3 - Significant Accounting Policies (Details) - Property, Plant and Equipment, Estimated Useful Lives [Line Items]
Property, Plant and Equipmen	5 years
Computer Equipment [Member]
Note 3 - Significant Accounting Policies (Details) - Property, Plant and Equipment, Estimated Useful Lives [Line Items]
Property, Plant and Equipmen	3 years
Software and Software Development Costs [Member]
Note 3 - Significant Accounting Policies (Details) - Property, Plant and Equipment, Estimated Useful Lives [Line Items]
Property, Plant and Equipmen	2 years
Equipment [Member] | Minimum [Member]
Note 3 - Significant Accounting Policies (Details) - Property, Plant and Equipment, Estimated Useful Lives [Line Items]
Property, Plant and Equipmen	5 years
Equipment [Member] | Maximum [Member]
Note 3 - Significant Accounting Policies (Details) - Property, Plant and Equipment, Estimated Useful Lives [Line Items]
Property, Plant and Equipmen	7 years
Tools, Dies and Molds [Member]
Note 3 - Significant Accounting Policies (Details) - Property, Plant and Equipment, Estimated Useful Lives [Line Items]
Property, Plant and Equipmen	2 years
Leasehold Improvements [Member]
Note 3 - Significant Accounting Policies (Details) - Property, Plant and Equipment, Estimated Useful Lives [Line Items]
Leasehold improvements	Initial term of lease

Note_5_Fair_Value_Measurements2

Note 5 - Fair Value Measurements (Details) (CAD)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 5 - Fair Value Measurements (Details) [Line Items]
Fair Value Inputs, Discount Rate	11.00%
Derivative Liability, Current	1,249,000	5,251,000
Warrant [Member] | Pro Forma [Member]
Note 5 - Fair Value Measurements (Details) [Line Items]
Fair Value Measurement, Liability, Impact of 5 Percent Change in Volatility	82,000	100,000
Warrant [Member]
Note 5 - Fair Value Measurements (Details) [Line Items]
Derivative Liability, Current	1,200,000

Note_5_Fair_Value_Measurements3

Note 5 - Fair Value Measurements (Details) - Financial Instrument Carried at Fair Value (CAD)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant Liability	1,249	5,251
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant Liability	1,249	5,251

Note_5_Fair_Value_Measurements4

Note 5 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities (CAD)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 5 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]
Warrant Liability	5,251
Warrant Liability	-4,002	2,114	364
Warrant Liability	1,249	5,251
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Note 5 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]
Warrant Liability	5,251
Warrant Liability	-4,002
Warrant Liability	1,249
Fair Value, Inputs, Level 3 [Member]
Note 5 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]
Warrant Liability	1,249	5,251

Note_5_Fair_Value_Measurements5

Note 5 - Fair Value Measurements (Details) - Quantitative Information about Unobservable Inputs (Warrant [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Warrant Liability	Option Model
Warrant Liability	106.00%	140.00%

Note_6_Financial_Instruments_D

Note 6 - Financial Instruments (Details) (CAD)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 6 - Financial Instruments (Details) [Line Items]
Allowance for Doubtful Accounts Receivable		6,000
Allowance for Doubtful Accounts Receivable, Write-offs	8,000
Four Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Note 6 - Financial Instruments (Details) [Line Items]
Concentration Risk, Percentage	87.00%
Three Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Note 6 - Financial Instruments (Details) [Line Items]
Concentration Risk, Percentage		74.00%

Note_6_Financial_Instruments_D1

Note 6 - Financial Instruments (Details) - Repayable Leasehold Improvement Allowance (CAD)	Dec. 31, 2014
In Thousands, unless otherwise specified
Note 6 - Financial Instruments (Details) - Repayable Leasehold Improvement Allowance [Line Items]
Accounts payable and accrued liabilities	3,867
2015	4,874
2016	1,242
2017	877
2018	640
2019	714
Thereafter	2,766
Term Loan [Member]
Note 6 - Financial Instruments (Details) - Repayable Leasehold Improvement Allowance [Line Items]
2015	546
2016	728
2017	303
2018	0
2019	0
Thereafter	0
Repayable Leasehold Improvement Allowance [Member]
Note 6 - Financial Instruments (Details) - Repayable Leasehold Improvement Allowance [Line Items]
2015	461
2016	514
2017	574
2018	640
2019	714
Thereafter	2,766

Note_7_Inventories_Details

Note 7 - Inventories (Details) (CAD)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 7 - Inventories (Details) [Line Items]
Inventory Write-down	285,000	25,000	217,000
Expired and Damaged [Member]
Note 7 - Inventories (Details) [Line Items]
Inventory Valuation Reserves	135,000	60,000

Note_7_Inventories_Details_Inv

Note 7 - Inventories (Details) - Inventory (CAD)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Abstract]
Raw materials	1,212	1,155
Work in progress	309	198
Finished goods	535	897
	2,056	2,250

Note_8_Property_Plant_and_Equi2

Note 8 - Property, Plant and Equipment (Details) (CAD)	Dec. 31, 2014	Dec. 31, 2013
Note 8 - Property, Plant and Equipment (Details) [Line Items]
Property, Plant and Equipment, Net	6,250,000	6,819,000
Equipment Not Ready for Use [Member]
Note 8 - Property, Plant and Equipment (Details) [Line Items]
Property, Plant and Equipment, Net	187,000	4,000

Note_8_Property_Plant_and_Equi3

Note 8 - Property, Plant and Equipment (Details) - Property, Plant and Equipment (CAD)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Equipment, Cost	15,837,000	15,412,000
Equipment, Accumulated Amortization	9,587,000	8,593,000
Equipment, Net book Value	6,250,000	6,819,000
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	964,000	964,000
Equipment, Accumulated Amortization	959,000	954,000
Equipment, Net book Value	5,000	10,000
Office Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	434,000	358,000
Equipment, Accumulated Amortization	354,000	311,000
Equipment, Net book Value	80,000	47,000
Laboratory Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	585,000	585,000
Equipment, Accumulated Amortization	578,000	575,000
Equipment, Net book Value	7,000	10,000
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	596,000	521,000
Equipment, Accumulated Amortization	509,000	476,000
Equipment, Net book Value	87,000	45,000
Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	136,000	109,000
Equipment, Accumulated Amortization	101,000	70,000
Equipment, Net book Value	35,000	39,000
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	2,709,000	2,472,000
Equipment, Accumulated Amortization	2,019,000	1,801,000
Equipment, Net book Value	690,000	671,000
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	603,000	603,000
Equipment, Accumulated Amortization	603,000	603,000
Equipment, Net book Value		0
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	9,810,000	9,800,000
Equipment, Accumulated Amortization	4,464,000	3,803,000
Equipment, Net book Value	5,346,000	5,997,000

Note_8_Property_Plant_and_Equi4

Note 8 - Property, Plant and Equipment (Details) - Depreciation Expense Allocation (CAD)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 8 - Property, Plant and Equipment (Details) - Depreciation Expense Allocation [Line Items]
Type of cost	994	992	1,143
Cost of Sales [Member]
Note 8 - Property, Plant and Equipment (Details) - Depreciation Expense Allocation [Line Items]
Type of cost	628	614	676
Research and Development Expense [Member]
Note 8 - Property, Plant and Equipment (Details) - Depreciation Expense Allocation [Line Items]
Type of cost	241	252	307
General and Administrative Expense [Member]
Note 8 - Property, Plant and Equipment (Details) - Depreciation Expense Allocation [Line Items]
Type of cost	66	73	91
Selling and Marketing Expense [Member]
Note 8 - Property, Plant and Equipment (Details) - Depreciation Expense Allocation [Line Items]
Type of cost	59	53	69

Note_9_Accounts_Payable_and_Ac2

Note 9 - Accounts Payable and Accrued Liabilities (Details) (Deferred Financing Costs [Member], CAD)	Dec. 31, 2014
Deferred Financing Costs [Member]
Note 9 - Accounts Payable and Accrued Liabilities (Details) [Line Items]
Accrued Liabilities and Other Liabilities	15,000

Note_9_Accounts_Payable_and_Ac3

Note 9 - Accounts Payable and Accrued Liabilities (Details) - Accounts Payable and Accrued Liabilities (CAD)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts Payable and Accrued Liabilities [Abstract]
Trade accounts payable	1,624	1,232
Employee related accounts payable and accrued liabilities	1,307	913
Royalties	287	172
Other accrued liabilities	649	410
	3,867	2,727

Note_10_Lease_Inducements_Deta

Note 10 - Lease Inducements (Details) (CAD)	12 Months Ended			181 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2023
Note 10 - Lease Inducements (Details) [Line Items]
Interest Expense	874,000	696,000	734,000
Letter of Credit [Member]
Note 10 - Lease Inducements (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	871,000
Line of Credit Facility, Collateral				$871,000
Lease Incentive One [Member]
Note 10 - Lease Inducements (Details) [Line Items]
Amortization of Lease Incentives, Lessee	54,000	54,000	54,000
Lease Incentive Two [Member]
Note 10 - Lease Inducements (Details) [Line Items]
Amortization of Lease Incentives, Lessee	115,000	115,000	115,000
Allowance for Leasehold Improvement, Non-repayable				1,700,000
Lease Incentive Three [Member] | Monthly [Member]
Note 10 - Lease Inducements (Details) [Line Items]
Allowance for Leasehold Improvement, Repayable				89,000
Lease Incentive Three [Member]
Note 10 - Lease Inducements (Details) [Line Items]
Amortization of Lease Incentives, Lessee	413,000	370,000	332,000
Allowance for Leasehold Improvement, Repayable				7,800,000
Interest Expense	649,000	691,000	730,000

Note_10_Lease_Inducements_Deta1

Note 10 - Lease Inducements (Details) - Summary of Lease Inducements (CAD)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Current Portion
Lease Incentive Payable, Current	169		170
Repayable leasehold improvement allowance [iii]	461	[1]	413	[1]
Total Current Portion	630		583
Long-Term Portion
Lease Incentive Payable, Noncurrent	1,197		1,366
Repayable leasehold improvement allowance [iii]	5,208	[1]	5,669	[1]
Total Long-Term Portion	6,405		7,035
Total	7,035		7,618
Rent-free Inducement [Member]
Current Portion
Lease Incentive Payable, Current	54	[2]	55	[2]
Long-Term Portion
Lease Incentive Payable, Noncurrent	385	[2]	439	[2]
Repayable Leasehold Improvement Allowance [Member]
Current Portion
Lease Incentive Payable, Current	115	[3]	115	[3]
Long-Term Portion
Lease Incentive Payable, Noncurrent	812	[3]	927	[3]
[1]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the year ended December 31, 2014 amounted to $413,000 [2013 - $370,000; 2012 - $332,000], respectively. Interest payments for the year ended December 31, 2014 amounted to $649,000 [2013 - $691,000; 2012 - $730,000].
[2]	In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense Amortization expense for the year ended December 31, 2014 amounted to $54,000 [2013 - $54,000; 2012 - $54,000].
[3]	The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the year ended December 31, 2014 amounted to $115,000 [2013 - $115,000; 2012 - $115,000].

Note_11_Term_Loan_Details

Note 11 - Term Loan (Details)

12 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2014

Dec. 15, 2014

Feb. 11, 2014

Dec. 15, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Dec. 15, 2014

Feb. 11, 2014

Feb. 11, 2014

Dec. 31, 2014

Dec. 15, 2014

Feb. 11, 2014

CAD

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Tranche 1 [Member]

Tranche 2 [Member]

Prime Rate [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

CAD

CAD

CAD

CAD

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

CAD

USD ($)

CAD

CAD

USD ($)

USD ($)

USD ($)

Note 11 - Term Loan (Details) [Line Items]

Term Loan, Maximum Borrowing Capacity (in Dollars)

$1,500,000

$1,000,000

$2,500,000

Debt Instrument, Basis Spread on Variable Rate

2.50%

Debt Instrument, Periodic Payment, Number of Installments

26

32

Class of Warrant or Right, Issued During Period (in Shares)

54,905

52,796

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

1

1.831

Fair Value Assumptions, Risk Free Interest Rate

1.57%

2.04%

Fair Value Assumptions, Expected Dividend Rate

0.00%

0.00%

Fair Value Assumptions, Expected Term

10 years

10 years

Fair Value Assumptions, Expected Volatility Rate

112.00%

110.00%

Fair Value of Warrant (in Dollars)

40,000

73,000

Debt Issuance Cost (in Dollars)

9,000

224,000

Debt Instrument, Face Amount (in Dollars)

1,400,000

Final Payment, Percentage of Principal

4.00%

Amortization of Financing Costs

99,000

99,000

Amortization of Debt Discount (Premium)

34,000

34,000

Note_11_Term_Loan_Details_Term

Note 11 - Term Loan (Details) - Term Loan Componnets (CAD)	Dec. 31, 2014
In Thousands, unless otherwise specified
Term Loan Componnets [Abstract]
Current portion of term loan	546
Current portion of unamortized debt discount	-52
Current portion of term loan, net debt discount	494
Long-term portion of term loan	1,031
Long-term portion of unamortized debt discount	-27
Long-term portion of term loan, net debt discount	1,004
Total	1,498

Note_11_Term_Loan_Details_Futu

Note 11 - Term Loan (Details) - Future Principal Payments for Term Loan (Incomplete) (CAD)	Dec. 31, 2014
In Thousands, unless otherwise specified
Note 11 - Term Loan (Details) - Future Principal Payments for Term Loan (Incomplete) [Line Items]
2015	4,874
2016	1,242
2017	877
2018	640
2019	714
Thereafter	2,766
Term Loan [Member]
Note 11 - Term Loan (Details) - Future Principal Payments for Term Loan (Incomplete) [Line Items]
2015	546
2016	728
2017	303
2018	0
2019	0
Thereafter	0
Total	1,577

Note_12_Share_Capital_and_Addi2

Note 12 - Share Capital and Additional Paid-in Capital (Details) (CAD)	0 Months Ended		12 Months Ended			0 Months Ended
	Nov. 07, 2013	Sep. 03, 2008	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 12, 2014	Dec. 15, 2014	Feb. 11, 2014
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period Value Private Placement, Gross (in Dollars)	3,100,000
Proceeds from Issuance of Private Placement (in Dollars)			2,024,000	2,055,000	0
Stock Issued during Period Value Private Placement, Net (in Dollars)	2,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			1,951,912
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			1,007,629	1,130,628	989,064
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			944,283
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)			357,000	605,000	355,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)				31,000	2,000
Stock Issued During Period, Value, Restricted Stock Award, Gross (in Dollars)			160,000	223,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)			306,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years
Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Private Placement [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Shares, New Issues						1,800,000
Sale of Stock, Price Per Share (in Dollars per share)						1.21
Stock Issued During Period Value Private Placement, Gross (in Dollars)						2,178,000
Hangzhou Joinstar Biomedical Co. Ltd. [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Sale of Stock, Price Per Share (in Dollars per share)						1.21
Proceeds from Issuance of Private Placement (in Dollars)						2,024,000
Payments of Financing Costs (in Dollars)						154,000
Warrant [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			86,865,691	86,757,990
Equity Option [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			1,007,629	1,130,628
Restricted Stock Units (RSUs) [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			136,348	98,325
Related to 2011 Financing [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding			86,103,744
Agent Warrants [Member] | Common Stock [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			2.45
Class of Warrant or Right, Outstanding			17,689
Silicon Valley Bank [Member] | Warrant [Member] | Common Share Price $1.83 [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			1.831
Class of Warrant or Right, Outstanding			52,796
Silicon Valley Bank [Member] | Warrant [Member] | Common Share Price 1.00 [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			1
Class of Warrant or Right, Outstanding			54,905
Silicon Valley Bank [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)							1	1.831
Private Placement [Member] | Common Stock [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			1,800,000	1,273,117
Private Placement [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,273,117
Common Stock [Member] | Private Placement [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			3.58
Class of Warrant or Right, Outstanding			636,557
Common Stock [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				122,458
Stock Issued during Period Value Private Placement, Net (in Dollars)	2,100,000
Class of Warrant or Right, Outstanding			86,865,691
Warrant [Member] | Private Placement [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			1.492
Warrant [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued during Period Value Private Placement, Net (in Dollars)	677,000
Restricted Stock Units (RSUs) [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			243,989
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			107,641
Deferred Share Unit Plan (DSUs) [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			243,989
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			243,989
Private Placement [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Sale of Stock, Price Per Share (in Dollars per share)	2.45
Payments of Financing Costs (in Dollars)	388,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	3.58

Note_12_Share_Capital_and_Addi3

Note 12 - Share Capital and Additional Paid-in Capital (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions (CAD)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]
Risk-free interest rates	1.98%	1.69%	1.68%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life (in years)	5 years 350 days	5 years 277 days	5 years 346 days
Expected volatility	126.00%	123.00%	113.00%
Fair value per stock option (in Dollars per share)	1.2	2.63	1.57

Note_12_Share_Capital_and_Addi4

Note 12 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding (CAD)	12 Months Ended
	Dec. 31, 2014
Range One [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- upper	0.88
Number of shares under option (in Shares)	115,790
Weighted average remaining contractual life	9 years 321 days
Weighted average exercise price	0.88
Range Two [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	1.02
Range of exercise price- upper	1.8
Number of shares under option (in Shares)	314,454
Weighted average remaining contractual life	8 years 167 days
Weighted average exercise price	1.46
Number of options currently exercisable (in Shares)	111,037
Weighted average exercise price - exercisable	1.4
Range Three [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- upper	2.2
Number of shares under option (in Shares)	388,861
Weighted average remaining contractual life	7 years 94 days
Weighted average exercise price	2.2
Number of options currently exercisable (in Shares)	348,122
Weighted average exercise price - exercisable	2.2
Range Four [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	3
Range of exercise price- upper	3.1
Number of shares under option (in Shares)	186,700
Weighted average remaining contractual life	8 years 80 days
Weighted average exercise price	3.1
Number of options currently exercisable (in Shares)	159,877
Weighted average exercise price - exercisable	3.1
Range Five [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	6.8
Range of exercise price- upper	8.2
Number of shares under option (in Shares)	1,824
Weighted average remaining contractual life	1 year 43 days
Weighted average exercise price	7.7
Number of options currently exercisable (in Shares)	1,496
Weighted average exercise price - exercisable	7.89
Range Six [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	0.88
Range of exercise price- upper	8.2
Number of shares under option (in Shares)	1,007,629
Weighted average remaining contractual life	8 years 36 days
Weighted average exercise price	1.99
Number of options currently exercisable (in Shares)	620,532
Weighted average exercise price - exercisable	2.3

Note_12_Share_Capital_and_Addi5

Note 12 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Activity (CAD)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Options, Activity [Abstract]
Balance, number of optioned common shares	1,130,628	989,064
Balance, weighted average exercise price	2.08	1.98
Options granted, number of optioned common shares	506,780	215,170
Options granted, weighted average exercise price	1.36	3.03
Options forfeited, number of optioned common shares	-629,194	-68,926
Options forfeited, weighted average exercise price	1.62	2.32
Options expired, number of optioned common shares	-585	-4,680
Options expired, weighted average exercise price	23	21.94
Balance, number of optioned common shares	1,007,629	1,130,628
Balance, weighted average exercise price	1.99	2.08

Note_12_Share_Capital_and_Addi6

Note 12 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan (CAD)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 12 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan [Line Items]
Balance, weighted average exercise price	1.99	2.08	1.98
RSUs granted, weighted average exercise price	1.36	3.03
Restricted Stock Units (RSUs) [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan [Line Items]
Balance	136,348	98,325	0
Balance, weighted average exercise price	1.39	1.88	0
RSUs granted	126,688	118,439
RSUs granted, weighted average exercise price	1.27	1.89
RSUs converted to common shares	-88,665	-20,114
RSUs converted to common shares, weighted average exercise price	1.75	1.93

Note_12_Share_Capital_and_Addi7

Note 12 - Share Capital and Additional Paid-in Capital (Details) - Allocation of Stock-based Compensation, by Type of Cost (CAD)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	381	660	614
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	36	29	27
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	45	44	48
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	259	551	528
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	41	36	11

Note_12_Share_Capital_and_Addi8

Note 12 - Share Capital and Additional Paid-in Capital (Details) - Warrants Activities (Warrant [Member], CAD)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]
Class of Warrant or Right [Line Items]
Number of warrants	86,865,691	86,757,990	89,976,289
Weighted average exercise price (in Dollars per share)	0.1024	0.1008	0.0746
Warrants issued, Number of warrants	107,701	654,246
Warrants issued, Weighted average exercise price (in Dollars)	1.4074	3.55
Exercise of warrants		-3,872,545
Exercise of warrants (in Dollars per share)		0.0746

Note_12_Share_Capital_and_Addi9

Note 12 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued (Warrant [Member], CAD)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Note 12 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued [Line Items]
Risk-free interest rates	1.00%	1.10%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	2 years	3 years
Expected volatility	111.00%	140.00%
Fair value of warrant (in Dollars)	0.0355	0.061

Note_13_Related_Party_Transact1

Note 13 - Related Party Transactions (Details)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 12, 2014

Dec. 12, 2014

Oct. 22, 2014

Oct. 15, 2014

Dec. 31, 2014

Dec. 12, 2014

Nov. 07, 2013

Nov. 07, 2013

Dec. 31, 2014

Dec. 31, 2013

Nov. 07, 2013

CAD

CAD

CAD

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

OrbiMed [Member]

OrbiMed [Member]

Director [Member]

Director [Member]

Private Placement [Member]

Director [Member]

Director [Member]

Director [Member]

Private Placement [Member]

CAD

USD ($)

USD ($)

CAD

CAD

Private Placement [Member]

CAD

Accounts Payable and Accrued Liabilities [Member]

Accounts Payable and Accrued Liabilities [Member]

CAD

CAD

CAD

CAD

CAD

Note 13 - Related Party Transactions (Details) [Line Items]

Shares Issued during Period in Private Placement (in Shares)

1,800,000

Share Price (in Dollars per share)

1.21

Proceeds from Issuance of Private Placement

2,024,000

2,055,000

0

2,024,000

Ownership Percentage of Company

18.40%

Cash Proceeds from Technology Development Agreement (in Dollars)

560,000

560,000

Contracts Revenue

186,000

186,000

Stock Issued During Period, Shares, New Issues (in Shares)

1,800,000

816,325

1,273,117

Common Stock, Shares, Issued (in Shares)

816,325

Class of Warrant or Right, Issued During Period (in Shares)

408,162

Legal Fees

53,000

Professional Fees

0

0

174,000

Accrued Professional Fees, Current

0

0

Note_14_Income_Taxes_Details

Note 14 - Income Taxes (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
	CAD	USD ($)	CAD		Domestic Tax Authority [Member]	Domestic Tax Authority [Member]	State and Local Jurisdiction [Member]	State and Local Jurisdiction [Member]
					CAD	CAD	CAD	CAD
Note 14 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	60,036,000		60,900,000
Tax Credit Carryforward, Amount					3,100,000	2,700,000	794,000	679,000
Unclaimed Tax Deductions, Research and Development carryforward	12,500,000	11,800,000
Other Deductible Temporary Differences	19,800,000		17,900,000
Deferred Tax Assets, Net of Valuation Allowance	0		0
Effective Income Tax Rate Reconciliation, Percent	26.00%	25.00%	25.00%	25.00%
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	44,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	24,000

Note_14_Income_Taxes_Details_L

Note 14 - Income Taxes (Details) - Losses and Investment Tax Credits Expiration (CAD)	Dec. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	60,036,000	60,900,000
State and Local Jurisdiction [Member] | Tax Credits Expire in Next Twelve Months [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	58,000
State and Local Jurisdiction [Member] | Tax Credits Expire in 2nd Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	142,000
State and Local Jurisdiction [Member] | Tax Credits Expire in 3rd Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	205,000
State and Local Jurisdiction [Member] | Tax Credits Expire in 4th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	198,000
State and Local Jurisdiction [Member] | Tax Credits Expire in 5th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	56,000
State and Local Jurisdiction [Member] | Tax Credits Expire in 7th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	28,000
State and Local Jurisdiction [Member] | Tax Credits Expire in 8th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	53,000
State and Local Jurisdiction [Member] | Tax Credits Expire in 9th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	20,000
State and Local Jurisdiction [Member] | Tax Credits Expire in 10th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	34,000
State and Local Jurisdiction [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	794,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	794,000	679,000
Domestic Tax Authority [Member] | Tax Credits Expire in 4th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	151,000
Domestic Tax Authority [Member] | Tax Credits Expire in 5th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	227,000
Domestic Tax Authority [Member] | Tax Credits Expire in 6th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	430,000
Domestic Tax Authority [Member] | Tax Credits Expire in 7th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	384,000
Domestic Tax Authority [Member] | Tax Credits Expire in 8th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	233,000
Domestic Tax Authority [Member] | Tax Credits Expire in 9th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	168,000
Domestic Tax Authority [Member] | Tax Credits Expire in 10th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	36,000
Domestic Tax Authority [Member] | Tax Credits Expire in 11th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	105,000
Domestic Tax Authority [Member] | Tax Credits Expire in 12th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	256,000
Domestic Tax Authority [Member] | Tax Credits Expire in 13th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	370,000
Domestic Tax Authority [Member] | Tax Credits Expire in 14th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	357,000
Domestic Tax Authority [Member] | Tax Credits Expire in 15th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	101,000
Domestic Tax Authority [Member] | Tax Credits Expire in 17th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	50,000
Domestic Tax Authority [Member] | Tax Credits Expire in 18th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	96,000
Domestic Tax Authority [Member] | Tax Credits Expire in 19th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	35,000
Domestic Tax Authority [Member] | Tax Credits Expire in 20th Year [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	61,000
Domestic Tax Authority [Member] | Investment Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	3,060,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Tax credit	3,100,000	2,700,000
Tax Credits Expire in Next Twelve Months [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	6,880,000
Tax Credits Expire in 12th Year [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	7,669,000
Tax Credits Expire in 13th Year [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	8,560,000
Tax Credits Expire in 14th Year [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	4,107,000
Tax Credits Expire in 15th Year [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	7,217,000
Tax Credits Expire in 16th Year [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	9,266,000
Tax Credits Expire in 17th Year [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	5,796,000
Tax Credits Expire in 18th Year [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	3,887,000
Tax Credits Expire in 19th Year [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	3,166,000
Tax Credits Expire in 20th Year [Member]
Operating Loss Carryforwards [Line Items]
Non-capital loss carryforwards	3,488,000

Note_14_Income_Taxes_Details_S

Note 14 - Income Taxes (Details) - Significant Components of Deferred Tax Assets (CAD)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Future Tax Assets:
Book amortization in excess of tax capital cost allowance	2,647	2,296
Non-capital loss carry forwards	15,609	15,222
Research and development deductions and credits	6,336	6,001
Share issue costs	113	169
Unearned revenue	227	22
Free rent liability	110	124
Non-repayable lease inducements	232	260
Repayable lease inducements	1,417	1,521
Other	86	83
Total future tax assets	26,777	25,698
Valuation allowance	-26,777	-25,698
Net future tax assets	0	0

Note_14_Income_Taxes_Details_E

Note 14 - Income Taxes (Details) - Effective Income Tax Rate Reconciliation (CAD)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation [Abstract]
Income tax recovery at statutory rates	-526	-1,500	-1,318
Tax expense of other tax jurisdictions	68	41
Expenses not deductible for tax purposes	-923	691	247
Non-capital losses for which no benefit has been recognized	907	755	1,082
Other temporary differences for which no benefit has been recognized	542	54	-11
Total income tax expense	68	41

Note_14_Income_Taxes_Details_R

Note 14 - Income Taxes (Details) - Reconciliation of Unrecognized Tax Benefits of Uncertain Tax Positions (CAD)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits of Uncertain Tax Positions [Abstract]
Balance at December 31	44	44	44
Additions based on tax positions related to the current year	0

Note_15_Commitments_Details

Note 15 - Commitments (Details) (CAD)	12 Months Ended			24 Months Ended	97 Months Ended	12 Months Ended	22 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2007	Jan. 31, 2023	Sep. 09, 2015	Sep. 17, 2014
Note 15 - Commitments (Details) [Line Items]
Royalty Expense				2,000,000
Operating Leases, Rent Expense, Net	802,000	807,000	779,000
West Nile Virus [Member]
Note 15 - Commitments (Details) [Line Items]
Royalty Expense	49,000	56,000	42,000
Developed Technology Rights [Member]
Note 15 - Commitments (Details) [Line Items]
Royalty Expense	628,000	616,000	634,000
Operation Facility [Member]
Note 15 - Commitments (Details) [Line Items]
Operating Lease, Monthly Payments					173,000
Office in China [Member]
Note 15 - Commitments (Details) [Line Items]
Operating Lease, Monthly Payments						8,000	5,000

Note_15_Commitments_Details_Mi

Note 15 - Commitments (Details) - Minimum Annual Cost of Lease Commitments (CAD)	Dec. 31, 2014
In Thousands, unless otherwise specified
Note 15 - Commitments (Details) - Minimum Annual Cost of Lease Commitments [Line Items]
2015	2,093
2016	2,112
2017	2,131
2018	2,160
2019	2,190
Thereafter	6,949
	17,635
Land and Building [Member]
Note 15 - Commitments (Details) - Minimum Annual Cost of Lease Commitments [Line Items]
2015	2,074
2016	2,102
2017	2,130
2018	2,160
2019	2,190
Thereafter	6,949
	17,605
Equipment [Member]
Note 15 - Commitments (Details) - Minimum Annual Cost of Lease Commitments [Line Items]
2015	19
2016	10
2017	1
	30

Note_15_Commitments_Details_Mi1

Note 15 - Commitments (Details) - Minimum Annual Purchase Commitments (CAD)	Dec. 31, 2014
In Thousands, unless otherwise specified
Minimum Annual Purchase Commitments [Abstract]
2015	1,163
2016	133
2017	175
2018	195
2019	150
	1,816

Note_16_Segmented_Information_1

Note 16 - Segmented Information (Details) (CAD)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Two Customers [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 16 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage	58.00%	50.00%	66.00%
Two Customers [Member]
Note 16 - Segmented Information (Details) [Line Items]
Revenues (in Dollars)	6.3	5.8	7.7
Customer One [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 16 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage	33.00%	36.00%	48.00%
Customer Two [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 16 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage	25.00%	14.00%	18.00%

Note_16_Segmented_Information_2

Note 16 - Segmented Information (Details) - Product Sales by Customer Location (CAD)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 16 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	10,828	11,531	11,750
CHINA
Note 16 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	6,905	7,153	7,748
UNITED STATES
Note 16 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	1,246	1,670	1,124
Asia (excluding China) [Member]
Note 16 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	512	807	824
Europe [Member]
Note 16 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	1,304	1,121	1,081
CANADA
Note 16 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	73	35	30
Segment, Geographical, Groups of Countries, Group Three [Member]
Note 16 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	788	745	943

Note_16_Segmented_Information_3

Note 16 - Segmented Information (Details) - Product Sales by Type of Product (CAD)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Product sales	10,828	11,531	11,750
Cardiovascular [Member]
Segment Reporting Information [Line Items]
Product sales	9,785	10,056	10,798
Infectious Diseases [Member]
Segment Reporting Information [Line Items]
Product sales	163	450	173
Bio-defense Products [Member]
Segment Reporting Information [Line Items]
Product sales	360	403	317
West Nile Virus [Member]
Segment Reporting Information [Line Items]
Product sales	520	622	462

Note_17_Subsequent_Events_Deta

Note 17 - Subsequent Events (Details) (Hangzhou Joinstar Biomedical Co. Ltd. [Member], USD $)	0 Months Ended
	Feb. 16, 2015	Oct. 22, 2014	Oct. 15, 2014
Note 17 - Subsequent Events (Details) [Line Items]
Cash Proceeds from Technology Development Agreement		$560,000	$560,000
Subsequent Event [Member]
Note 17 - Subsequent Events (Details) [Line Items]
Cash Proceeds from Technology Development Agreement	$720,000